-
1
-
-
46849085176
-
Imaging and cancer: a review
-
Fass L. Imaging and cancer: a review. Mol Oncol 2008, 2(2):115-152.
-
(2008)
Mol Oncol
, vol.2
, Issue.2
, pp. 115-152
-
-
Fass, L.1
-
2
-
-
84864557896
-
Molecular imaging and radiotherapy: theranostics for personalized patient management
-
Velikyan I. Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics: 2012, 2(1):424-426.
-
(2012)
Theranostics:
, vol.2
, Issue.1
, pp. 424-426
-
-
Velikyan, I.1
-
3
-
-
79958239211
-
Generator-based P.E.T. radiopharmaceuticals for molecular imaging of tumours: on the way to Theranostics
-
Rosch F., Baum R.P. Generator-based P.E.T. radiopharmaceuticals for molecular imaging of tumours: on the way to Theranostics. Dalton Trans 2011, 40:6104-6111.
-
(2011)
Dalton Trans
, vol.40
, pp. 6104-6111
-
-
Rosch, F.1
Baum, R.P.2
-
4
-
-
84859358363
-
Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms
-
Baum R.P., Kulkarni H.R., Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012, 42:190-207.
-
(2012)
Semin Nucl Med
, vol.42
, pp. 190-207
-
-
Baum, R.P.1
Kulkarni, H.R.2
Carreras, C.3
-
5
-
-
84864545273
-
Theranostics: from molecular imaging using Ga-68 Labeled tracers and PET/CT to personalized radionuclide therapy-the bad berka experience
-
Baum R.P., Kulkarni H.R. Theranostics: from molecular imaging using Ga-68 Labeled tracers and PET/CT to personalized radionuclide therapy-the bad berka experience. Theranostics 2012, 2:437-447.
-
(2012)
Theranostics
, vol.2
, pp. 437-447
-
-
Baum, R.P.1
Kulkarni, H.R.2
-
6
-
-
0036677602
-
Reinventing pharma: the theranostic revolution
-
Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discovery 2002, 17-19.
-
(2002)
Curr Drug Discovery
, pp. 17-19
-
-
Funkhouser, J.1
-
7
-
-
38549096283
-
Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology
-
Schoder H., Ong S.C. Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. Semin Nucl Med 2008, 38:119-128.
-
(2008)
Semin Nucl Med
, vol.38
, pp. 119-128
-
-
Schoder, H.1
Ong, S.C.2
-
8
-
-
84902388598
-
-
World Nuclear Association. Radioisotopes in Medicine
-
World Nuclear Association. Radioisotopes in Medicine. 2014. Available at: . http://www.world-nuclear.org/info/inf55.html.
-
(2014)
-
-
-
9
-
-
83755220922
-
Status of and trends in nuclear medicine in the United States
-
Delbeke D., Segall G.M. Status of and trends in nuclear medicine in the United States. J Nucl Med 2011, 52:24S-28SS.
-
(2011)
J Nucl Med
, vol.52
-
-
Delbeke, D.1
Segall, G.M.2
-
10
-
-
0035021707
-
A tabulated summary of the FDG PET literature
-
Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., Phelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 2001, 42:1S-93S.
-
(2001)
J Nucl Med
, vol.42
-
-
Gambhir, S.S.1
Czernin, J.2
Schwimmer, J.3
Silverman, D.H.4
Coleman, R.E.5
Phelps, M.E.6
-
11
-
-
33947640019
-
The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development
-
Lindsay M.J., Siegel B.A., Tunis S.R., Hillner B.E., Shields A.F., Carey B.P., et al. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development. Am J Roentgenol 2007, 188:1109-1113.
-
(2007)
Am J Roentgenol
, vol.188
, pp. 1109-1113
-
-
Lindsay, M.J.1
Siegel, B.A.2
Tunis, S.R.3
Hillner, B.E.4
Shields, A.F.5
Carey, B.P.6
-
12
-
-
79952034618
-
The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy
-
Wahl R.L., Herman J.M., Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol 2011, 21:88-100.
-
(2011)
Semin Radiat Oncol
, vol.21
, pp. 88-100
-
-
Wahl, R.L.1
Herman, J.M.2
Ford, E.3
-
13
-
-
41849104653
-
PET versus SPECT: strengths, limitations and challenges
-
Rahmim A., Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008, 29:193-207.
-
(2008)
Nucl Med Commun
, vol.29
, pp. 193-207
-
-
Rahmim, A.1
Zaidi, H.2
-
14
-
-
84872919693
-
Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET
-
Prieto E., Domínguez-Prado I., García-Velloso M.J., Peñuelas I., Richter J.A., Martí-Climent J.M. Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET. Clin Nuc Med 2013, 38:103-109.
-
(2013)
Clin Nuc Med
, vol.38
, pp. 103-109
-
-
Prieto, E.1
Domínguez-Prado, I.2
García-Velloso, M.J.3
Peñuelas, I.4
Richter, J.A.5
Martí-Climent, J.M.6
-
15
-
-
77950297123
-
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass
-
Velikyan I., Sundin A., Eriksson B., Lundqvist H., Sorensen J., Bergstrom M., et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol 2010, 37:265-275.
-
(2010)
Nucl Med Biol
, vol.37
, pp. 265-275
-
-
Velikyan, I.1
Sundin, A.2
Eriksson, B.3
Lundqvist, H.4
Sorensen, J.5
Bergstrom, M.6
-
16
-
-
78049234611
-
Combined PET/MRI: one step further in multimodality imaging
-
Sauter A.W., Wehrl H.F., Kolb A., Judenhofer M.S., Pichler B.J. Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 2010, 16:508-515.
-
(2010)
Trends Mol Med
, vol.16
, pp. 508-515
-
-
Sauter, A.W.1
Wehrl, H.F.2
Kolb, A.3
Judenhofer, M.S.4
Pichler, B.J.5
-
17
-
-
76049124693
-
Combined PET/MR imaging-technology and applications
-
Wehrl H.F., Sauter A.W., Judenhofer M.S., Pichler B.J. Combined PET/MR imaging-technology and applications. Tech Canc Res Treat 2010, 9:5-20.
-
(2010)
Tech Canc Res Treat
, vol.9
, pp. 5-20
-
-
Wehrl, H.F.1
Sauter, A.W.2
Judenhofer, M.S.3
Pichler, B.J.4
-
18
-
-
46849087258
-
Current trends in PET and combined (PET/CT and PET/MR) systems design
-
Zaidi H., Alavi A. Current trends in PET and combined (PET/CT and PET/MR) systems design. PET Clin 2007, 2:109-123.
-
(2007)
PET Clin
, vol.2
, pp. 109-123
-
-
Zaidi, H.1
Alavi, A.2
-
19
-
-
84862530385
-
Adverse events in nuclear medicine-cause for concern?
-
Hesse B., Vinberg N., Berthelsen A.K., Ballinger J.R. Adverse events in nuclear medicine-cause for concern?. Eur J Nucl Med Mol Imaging 2012, 39:782-785.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 782-785
-
-
Hesse, B.1
Vinberg, N.2
Berthelsen, A.K.3
Ballinger, J.R.4
-
20
-
-
84870464483
-
Is there still a role for SPECT-CT in oncology in the PET-CT era?
-
Hicks R.J., Hofman M.S. Is there still a role for SPECT-CT in oncology in the PET-CT era?. Nat Rev Clin Oncol 2012, 9:712-720.
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 712-720
-
-
Hicks, R.J.1
Hofman, M.S.2
-
21
-
-
84867906814
-
Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?
-
Hicks R.J. Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?. Cancer Imaging 2012, 12:315-323.
-
(2012)
Cancer Imaging
, vol.12
, pp. 315-323
-
-
Hicks, R.J.1
-
22
-
-
84861482093
-
Molecular imaging and contrast agent database (MICAD): Evolution and progress
-
Chopra A., Shan L., Eckelman W.C., Leung K., Latterner M., Bryant S.H., et al. Molecular imaging and contrast agent database (MICAD): Evolution and progress. Mol Imaging Biol 2012, 14:4-13.
-
(2012)
Mol Imaging Biol
, vol.14
, pp. 4-13
-
-
Chopra, A.1
Shan, L.2
Eckelman, W.C.3
Leung, K.4
Latterner, M.5
Bryant, S.H.6
-
23
-
-
83755206278
-
Issues and controversies in nuclear medicine. Introduction
-
Czernin J., Weber W.A. Issues and controversies in nuclear medicine. Introduction. J Nucl Med 2011, 52(Suppl 2):1S-2S.
-
(2011)
J Nucl Med
, vol.52
, Issue.SUPPL.2
-
-
Czernin, J.1
Weber, W.A.2
-
24
-
-
84865004051
-
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: A meta-analysis
-
Treglia G., Castaldi P., Rindi G., Giordano A., Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: A meta-analysis. Endocrine 2012, 42:80-87.
-
(2012)
Endocrine
, vol.42
, pp. 80-87
-
-
Treglia, G.1
Castaldi, P.2
Rindi, G.3
Giordano, A.4
Rufini, V.5
-
25
-
-
80052014406
-
68Ga]Ga-based imaging agents: chemistry and diversity
-
68Ga]Ga-based imaging agents: chemistry and diversity. Med Chem 2011, 7:338-372.
-
(2011)
Med Chem
, vol.7
, pp. 338-372
-
-
Velikyan, I.1
-
26
-
-
84864979948
-
Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?
-
Öberg K. Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?. Endocrine 2012, 42:3-4.
-
(2012)
Endocrine
, vol.42
, pp. 3-4
-
-
Öberg, K.1
-
27
-
-
84858778411
-
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours
-
Schreiter N.F., Brenner W., Nogami M., Buchert R., Huppertz A., Pape U.F., et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012, 39:72-82.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 72-82
-
-
Schreiter, N.F.1
Brenner, W.2
Nogami, M.3
Buchert, R.4
Huppertz, A.5
Pape, U.F.6
-
29
-
-
77955245741
-
How can we tell if PET imaging for cancer is cost effective?
-
Manus M.P.M., Hicks R.J. How can we tell if PET imaging for cancer is cost effective?. Lancet Oncol 2010, 11:711-712.
-
(2010)
Lancet Oncol
, vol.11
, pp. 711-712
-
-
Manus, M.P.M.1
Hicks, R.J.2
-
30
-
-
83755206208
-
Contribution of imaging to cancer care costs
-
Yang Y., Czernin J. Contribution of imaging to cancer care costs. J Nucl Med 2011, 52:86S-92S.
-
(2011)
J Nucl Med
, vol.52
-
-
Yang, Y.1
Czernin, J.2
-
31
-
-
84864544217
-
Lessons on tumour response: imaging during therapy with (177)Lu-DOTA-octreotate. a case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma
-
Garske U., Sandstrom M., Johansson S., Granberg D., Lundqvist H., Lubberink M., et al. Lessons on tumour response: imaging during therapy with (177)Lu-DOTA-octreotate. a case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma. Theranostics 2012, 2:459-471.
-
(2012)
Theranostics
, vol.2
, pp. 459-471
-
-
Garske, U.1
Sandstrom, M.2
Johansson, S.3
Granberg, D.4
Lundqvist, H.5
Lubberink, M.6
-
32
-
-
47049128631
-
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer
-
Hamoudeh M., Kamleh M.A., Diab R., Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008, 60:1329-1346.
-
(2008)
Adv Drug Deliv Rev
, vol.60
, pp. 1329-1346
-
-
Hamoudeh, M.1
Kamleh, M.A.2
Diab, R.3
Fessi, H.4
-
33
-
-
50449108120
-
119Sb--a potent Auger emitter for targeted radionuclide therapy
-
Thisgaard H., Jensen M. 119Sb--a potent Auger emitter for targeted radionuclide therapy. Med Phys 2008, 35:3839-3846.
-
(2008)
Med Phys
, vol.35
, pp. 3839-3846
-
-
Thisgaard, H.1
Jensen, M.2
-
34
-
-
84860332551
-
Synthesis of oncological [11C]radiopharmaceuticals for clinical PET
-
Lodi F., Malizia C., Castellucci P., Cicoria G., Fanti S., Boschi S. Synthesis of oncological [11C]radiopharmaceuticals for clinical PET. Nucl Med Biol 2012, 39:447-460.
-
(2012)
Nucl Med Biol
, vol.39
, pp. 447-460
-
-
Lodi, F.1
Malizia, C.2
Castellucci, P.3
Cicoria, G.4
Fanti, S.5
Boschi, S.6
-
35
-
-
77954955636
-
HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue
-
Tolmachev V., Velikyan I., Sandstrom M., Orlova A.A. HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010, 37:1356-1367.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 1356-1367
-
-
Tolmachev, V.1
Velikyan, I.2
Sandstrom, M.3
Orlova, A.A.4
-
36
-
-
84860140648
-
Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc
-
Pruszyński M., Majkowska-Pilip A., Loktionova N.S., Eppard E., Roesch F. Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc. Appl Radiat Isot 2012, 70:974-979.
-
(2012)
Appl Radiat Isot
, vol.70
, pp. 974-979
-
-
Pruszyński, M.1
Majkowska-Pilip, A.2
Loktionova, N.S.3
Eppard, E.4
Roesch, F.5
-
37
-
-
78049342773
-
Short- and long-term responses to molybdenum-99 shortages in nuclear medicine
-
Ballinger J.R. Short- and long-term responses to molybdenum-99 shortages in nuclear medicine. Br J Radiol 2010, 83:899-901.
-
(2010)
Br J Radiol
, vol.83
, pp. 899-901
-
-
Ballinger, J.R.1
-
38
-
-
84896727755
-
Production, radiochemical processing and quality evaluation of Ge-68 suitable for production of a 68Ge/68Ga generator.
-
Roesch F. Filosofov DV. Production, radiochemical processing and quality evaluation of Ge-68 suitable for production of a 68Ge/68Ga generator. Int. Atomic Energy Agency; 2010.
-
(2010)
Int. Atomic Energy Agency
-
-
Roesch, F.1
Filosofov, D.V.2
-
39
-
-
1642430605
-
Positron flight in human tissues and its influence on PET image spatial resolution
-
Sanchez-Crespo A., Andreo P., Larsson S.A. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 2004, 31:44-51.
-
(2004)
Eur J Nucl Med Mol Imaging
, vol.31
, pp. 44-51
-
-
Sanchez-Crespo, A.1
Andreo, P.2
Larsson, S.A.3
-
40
-
-
33846614453
-
High resolution PET imaging characteristics of Ga-68, I-124 and Zr-89 compared to F-18
-
vols 1-52005
-
de Jong H., Perk L., Visser G.W.M., Boellaard R., van Dongen G., Lammertsma A.A. High resolution PET imaging characteristics of Ga-68, I-124 and Zr-89 compared to F-18. IEEE Nuclear Science Symposium Conference Record 2005, vols 1-52005:1624-1627.
-
(2005)
IEEE Nuclear Science Symposium Conference Record
, pp. 1624-1627
-
-
de Jong, H.1
Perk, L.2
Visser, G.W.M.3
Boellaard, R.4
van Dongen, G.5
Lammertsma, A.A.6
-
41
-
-
77956991351
-
Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences
-
Coenen H.H., Elsinga P.H., Iwata R., Kilbourn M.R., Pillai M.R.A., Rajan M.G.R., et al. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. Nucl Med Biol 2010, 37:727-740.
-
(2010)
Nucl Med Biol
, vol.37
, pp. 727-740
-
-
Coenen, H.H.1
Elsinga, P.H.2
Iwata, R.3
Kilbourn, M.R.4
Pillai, M.R.A.5
Rajan, M.G.R.6
-
42
-
-
33845514222
-
Design of radiolabelled ligands for the imaging and treatment of cancer
-
Mather S.J. Design of radiolabelled ligands for the imaging and treatment of cancer. Mol Biosyst 2007, 3:30-35.
-
(2007)
Mol Biosyst
, vol.3
, pp. 30-35
-
-
Mather, S.J.1
-
43
-
-
84859620025
-
Clinical molecular imaging with radiotracers: current status
-
Graham M.M. Clinical molecular imaging with radiotracers: current status. Med Princ Pract 2012, 21:197-208.
-
(2012)
Med Princ Pract
, vol.21
, pp. 197-208
-
-
Graham, M.M.1
-
44
-
-
84859340442
-
Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory
-
Srivastava S.C. Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory. Semin Nucl Med 2012, 42:151-163.
-
(2012)
Semin Nucl Med
, vol.42
, pp. 151-163
-
-
Srivastava, S.C.1
-
45
-
-
84864536827
-
Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide re-ceptor radionuclide therapy with high activity in-111 pentetreotide
-
Delpassand E.S., Samarghandi A., Mourtada J.S., Zamanian S., Espenan G.D., Sharif R., et al. Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide re-ceptor radionuclide therapy with high activity in-111 pentetreotide. Theranostics 2012, 2:472-480.
-
(2012)
Theranostics
, vol.2
, pp. 472-480
-
-
Delpassand, E.S.1
Samarghandi, A.2
Mourtada, J.S.3
Zamanian, S.4
Espenan, G.D.5
Sharif, R.6
-
46
-
-
84859316607
-
Radioiodine: the classic theranostic agent
-
Silberstein E.B. Radioiodine: the classic theranostic agent. Semin Nucl Med 2012, 42:164-170.
-
(2012)
Semin Nucl Med
, vol.42
, pp. 164-170
-
-
Silberstein, E.B.1
-
47
-
-
44249114580
-
PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124
-
Herzog H., Tellmann L., Scholten B., Coenen H.H., Qaim S.M. PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124. Q J Nucl Med Mol Imaging 2008, 52:159-165.
-
(2008)
Q J Nucl Med Mol Imaging
, vol.52
, pp. 159-165
-
-
Herzog, H.1
Tellmann, L.2
Scholten, B.3
Coenen, H.H.4
Qaim, S.M.5
-
48
-
-
77958484636
-
Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy
-
Capala J., Bouchelouche K. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol 2010, 22:559-566.
-
(2010)
Curr Opin Oncol
, vol.22
, pp. 559-566
-
-
Capala, J.1
Bouchelouche, K.2
-
49
-
-
77951441898
-
"Image and treat": an individualized approach to urological tumors
-
Bouchelouche K., Capala J. "Image and treat": an individualized approach to urological tumors. Curr Opin Oncol 2010, 22:274-280.
-
(2010)
Curr Opin Oncol
, vol.22
, pp. 274-280
-
-
Bouchelouche, K.1
Capala, J.2
-
50
-
-
45449120466
-
The importance of high specific radioactivity in the performance of (68)Ga-labeled peptide
-
Velikyan I., Beyer G.J., Bergstrom-Pettermann E., Johansen P., Bergstrom M., Langstrom B. The importance of high specific radioactivity in the performance of (68)Ga-labeled peptide. Nucl Med Biol 2008, 35:529-536.
-
(2008)
Nucl Med Biol
, vol.35
, pp. 529-536
-
-
Velikyan, I.1
Beyer, G.J.2
Bergstrom-Pettermann, E.3
Johansen, P.4
Bergstrom, M.5
Langstrom, B.6
-
51
-
-
84878149570
-
Dosimetry of [(68)Ga]-labeled compounds
-
Eberlein U., Lassmann M. Dosimetry of [(68)Ga]-labeled compounds. Appl Radiat Isot 2012, 76:70-74.
-
(2012)
Appl Radiat Isot
, vol.76
, pp. 70-74
-
-
Eberlein, U.1
Lassmann, M.2
-
52
-
-
36849049710
-
(68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors
-
Pettinato C., Sarnelli A., Di Donna M., Civollani S., Nanni C., Montini G., et al. (68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008, 35:72-79.
-
(2008)
Eur J Nucl Med Mol Imaging
, vol.35
, pp. 72-79
-
-
Pettinato, C.1
Sarnelli, A.2
Di Donna, M.3
Civollani, S.4
Nanni, C.5
Montini, G.6
-
53
-
-
65649127261
-
Engineered affinity proteins for tumour-targeting applications
-
Friedman M., Ståhl S. Engineered affinity proteins for tumour-targeting applications. Biotechnol Appl Biochem 2009, 53:1-29.
-
(2009)
Biotechnol Appl Biochem
, vol.53
, pp. 1-29
-
-
Friedman, M.1
Ståhl, S.2
-
54
-
-
77954955682
-
68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours
-
Eder M., Knackmuss S., Le Gall F., Reusch U., Rybin V., Little M., et al. 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging 2010, 37:1397-1407.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 1397-1407
-
-
Eder, M.1
Knackmuss, S.2
Le Gall, F.3
Reusch, U.4
Rybin, V.5
Little, M.6
-
55
-
-
84878458335
-
Radiolabelled peptides in diagnosis and therapy: an introduction
-
Al-Nahhas A., Fanti S. Radiolabelled peptides in diagnosis and therapy: an introduction. Eur J Nucl Med Mol Imaging 2012, 39(Suppl 1):S1-S3.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, Issue.SUPPL.1
-
-
Al-Nahhas, A.1
Fanti, S.2
-
57
-
-
84863808443
-
Rationale for the use of radiolabelled peptides in diagnosis and therapy
-
Koopmans K.P., Glaudemans A.W. Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur J Nucl Med Mol Imaging 2012, 39(Suppl 1):S4-10.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, Issue.SUPPL.1
-
-
Koopmans, K.P.1
Glaudemans, A.W.2
-
58
-
-
84867048380
-
Old and new peptide receptor targets in cancer: future directions
-
Reubi J.C. Old and new peptide receptor targets in cancer: future directions. Recent Results Cancer Res 2013, 194:567-576.
-
(2013)
Recent Results Cancer Res
, vol.194
, pp. 567-576
-
-
Reubi, J.C.1
-
59
-
-
83755225132
-
Radiopeptide imaging and therapy in Europe
-
Ambrosini V., Fani M., Fanti S., Forrer F., Maecke H.R. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011, 52(Suppl 2):42S-55S.
-
(2011)
J Nucl Med
, vol.52
, Issue.SUPPL.2
-
-
Ambrosini, V.1
Fani, M.2
Fanti, S.3
Forrer, F.4
Maecke, H.R.5
-
60
-
-
79958120505
-
Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment
-
Maecke H.R., Reubi J.C. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 2011, 52:841-844.
-
(2011)
J Nucl Med
, vol.52
, pp. 841-844
-
-
Maecke, H.R.1
Reubi, J.C.2
-
61
-
-
80052365882
-
N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function
-
Erchegyi J., Cescato R., Waser B., Rivier J.E., Reubi J.C. N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function. J Med Chem 2011, 54:5981-5987.
-
(2011)
J Med Chem
, vol.54
, pp. 5981-5987
-
-
Erchegyi, J.1
Cescato, R.2
Waser, B.3
Rivier, J.E.4
Reubi, J.C.5
-
62
-
-
1842592125
-
A gallium-labeled DOTA-{alpha}-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases
-
Froidevaux S., Calame-Christe M., Schuhmacher J., Tanner H., Saffrich R., Henze M., et al. A gallium-labeled DOTA-{alpha}-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004, 45:116-123.
-
(2004)
J Nucl Med
, vol.45
, pp. 116-123
-
-
Froidevaux, S.1
Calame-Christe, M.2
Schuhmacher, J.3
Tanner, H.4
Saffrich, R.5
Henze, M.6
-
63
-
-
67349128040
-
Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A″-Re(Arg11)CCMSH
-
Wei L., Zhang X., Gallazzi F., Miao Y., Jin X., Brechbiel M.W., et al. Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A″-Re(Arg11)CCMSH. Nucl Med Biol 2009, 36:345-354.
-
(2009)
Nucl Med Biol
, vol.36
, pp. 345-354
-
-
Wei, L.1
Zhang, X.2
Gallazzi, F.3
Miao, Y.4
Jin, X.5
Brechbiel, M.W.6
-
64
-
-
34548119893
-
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours
-
Zhang H.W., Schuhmacher J., Waser B., Wild D., Eisenhut M., Reubi J.C., et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007, 34:1198-1208.
-
(2007)
Eur J Nucl Med Mol Imaging
, vol.34
, pp. 1198-1208
-
-
Zhang, H.W.1
Schuhmacher, J.2
Waser, B.3
Wild, D.4
Eisenhut, M.5
Reubi, J.C.6
-
65
-
-
48149103227
-
68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression
-
Decristoforo C., Hernandez Gonzalez I., Carlsen J., Rupprich M., Huisman M., Virgolini I., et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008, 35:1507-1515.
-
(2008)
Eur J Nucl Med Mol Imaging
, vol.35
, pp. 1507-1515
-
-
Decristoforo, C.1
Hernandez Gonzalez, I.2
Carlsen, J.3
Rupprich, M.4
Huisman, M.5
Virgolini, I.6
-
66
-
-
0033033382
-
Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy
-
Heppeler A., Froidevaux S., Macke H.R., Jermann E., Behe M., Powell P., et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem-Eur J. 1999, 5:1974-1981.
-
(1999)
Chem-Eur J.
, vol.5
, pp. 1974-1981
-
-
Heppeler, A.1
Froidevaux, S.2
Macke, H.R.3
Jermann, E.4
Behe, M.5
Powell, P.6
-
67
-
-
16544377125
-
Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology
-
Maecke H.R. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop 2005, 43-72.
-
(2005)
Ernst Schering Res Found Workshop
, pp. 43-72
-
-
Maecke, H.R.1
-
68
-
-
12344274317
-
Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides
-
Rivier J.E., Kirby D.A., Erchegyi J., Waser B., Eltschinger V., Cescato R., et al. Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem 2005, 48:515-522.
-
(2005)
J Med Chem
, vol.48
, pp. 515-522
-
-
Rivier, J.E.1
Kirby, D.A.2
Erchegyi, J.3
Waser, B.4
Eltschinger, V.5
Cescato, R.6
-
69
-
-
0141996533
-
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
-
Wild D., Schmitt J.S., Ginj M., Macke H.R., Bernard B.F., Krenning E., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003, 30:1338-1347.
-
(2003)
Eur J Nucl Med Mol Imaging
, vol.30
, pp. 1338-1347
-
-
Wild, D.1
Schmitt, J.S.2
Ginj, M.3
Macke, H.R.4
Bernard, B.F.5
Krenning, E.6
-
70
-
-
12944329895
-
Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy
-
Ginj M., Chen J., Walter M.A., Eltschinger V., Reubi J.C., Maecke H.R. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005, 11:1136-1145.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1136-1145
-
-
Ginj, M.1
Chen, J.2
Walter, M.A.3
Eltschinger, V.4
Reubi, J.C.5
Maecke, H.R.6
-
71
-
-
0032589981
-
Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery
-
Hofland L.J., Breeman W.A., Krenning E.P., de Jong M., Waaijers M., van Koetsveld P.M., et al. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Physicians 1999, 111:63-69.
-
(1999)
Proc Assoc Am Physicians
, vol.111
, pp. 63-69
-
-
Hofland, L.J.1
Breeman, W.A.2
Krenning, E.P.3
de Jong, M.4
Waaijers, M.5
van Koetsveld, P.M.6
-
72
-
-
0032579454
-
Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
-
De Jong M., Bakker W.H., Breeman W.A., Bernard B.F., Hofland L.J., Visser T.J., et al. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998, 75:406-411.
-
(1998)
Int J Cancer
, vol.75
, pp. 406-411
-
-
De Jong, M.1
Bakker, W.H.2
Breeman, W.A.3
Bernard, B.F.4
Hofland, L.J.5
Visser, T.J.6
-
73
-
-
0034033495
-
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
-
Reubi J.C., Schär J.-C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging 2000, 27:273-282.
-
(2000)
Eur J Nucl Med Mol Imaging
, vol.27
, pp. 273-282
-
-
Reubi, J.C.1
Schär, J.-C.2
Waser, B.3
Wenger, S.4
Heppeler, A.5
Schmitt, J.S.6
-
74
-
-
0036415073
-
Somatostatin analogs and radiopeptides in cancer therapy
-
Froidevaux S., Eberle A.N. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002, 66:161-183.
-
(2002)
Biopolymers
, vol.66
, pp. 161-183
-
-
Froidevaux, S.1
Eberle, A.N.2
-
75
-
-
4544291995
-
A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
-
Forrer F., Uusijarvi H., Waldherr C., Cremonesi M., Bernhardt P., Mueller-Brand J., et al. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004, 31:1257-1262.
-
(2004)
Eur J Nucl Med Mol Imaging
, vol.31
, pp. 1257-1262
-
-
Forrer, F.1
Uusijarvi, H.2
Waldherr, C.3
Cremonesi, M.4
Bernhardt, P.5
Mueller-Brand, J.6
-
76
-
-
18844396135
-
Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model
-
Schmitt A., Bernhardt P., Nilsson O., Ahlman H., Kolby L., Forssell-Aronsson E. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm 2005, 20:231-236.
-
(2005)
Cancer Biother Radiopharm
, vol.20
, pp. 231-236
-
-
Schmitt, A.1
Bernhardt, P.2
Nilsson, O.3
Ahlman, H.4
Kolby, L.5
Forssell-Aronsson, E.6
-
77
-
-
0027958185
-
Gallium-67/Gallium-68-[DFO]-Octreotide- a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies
-
Smith-Jones P.M., Stolz B., Burns C., Albert R., Reist H.W., Fridrich R., et al. Gallium-67/Gallium-68-[DFO]-Octreotide- a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994, 35:317-325.
-
(1994)
J Nucl Med
, vol.35
, pp. 317-325
-
-
Smith-Jones, P.M.1
Stolz, B.2
Burns, C.3
Albert, R.4
Reist, H.W.5
Fridrich, R.6
-
78
-
-
0037140131
-
Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model
-
Froidevaux S., Eberle A.N., Christe M., Sumanovski L., Heppeler A., Schmitt J.S., et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002, 98:930-937.
-
(2002)
Int J Cancer
, vol.98
, pp. 930-937
-
-
Froidevaux, S.1
Eberle, A.N.2
Christe, M.3
Sumanovski, L.4
Heppeler, A.5
Schmitt, J.S.6
-
79
-
-
0034949018
-
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-Octreotide: first results in patients with meningiomas
-
Henze M., Schuhmacher J., Hipp P., Kowalski J., Becker D.W., Doll J., et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-Octreotide: first results in patients with meningiomas. J Nucl Med 2001, 42:1053-1056.
-
(2001)
J Nucl Med
, vol.42
, pp. 1053-1056
-
-
Henze, M.1
Schuhmacher, J.2
Hipp, P.3
Kowalski, J.4
Becker, D.W.5
Doll, J.6
-
80
-
-
33745539394
-
Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using Ga-68-DOTATOC PET and comparison with F-18-FDG PET
-
Dimitrakopoulou-Strauss A., Georgoulias V., Eisenhut M., Herth F., Koukouraki S., Macke H.R., et al. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using Ga-68-DOTATOC PET and comparison with F-18-FDG PET. Eur J Nucl Med Mol Imaging 2006, 33:823-830.
-
(2006)
Eur J Nucl Med Mol Imaging
, vol.33
, pp. 823-830
-
-
Dimitrakopoulou-Strauss, A.1
Georgoulias, V.2
Eisenhut, M.3
Herth, F.4
Koukouraki, S.5
Macke, H.R.6
-
81
-
-
34547770763
-
Ga-68-Labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with F-18-FDG
-
Dimitrakopoulou-Strauss A., Hohenberger P., Haberkorn U., Macke H.R., Eisenhut M., Strauss L.G. Ga-68-Labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with F-18-FDG. J Nucl Med 2007, 48:1245-1250.
-
(2007)
J Nucl Med
, vol.48
, pp. 1245-1250
-
-
Dimitrakopoulou-Strauss, A.1
Hohenberger, P.2
Haberkorn, U.3
Macke, H.R.4
Eisenhut, M.5
Strauss, L.G.6
-
82
-
-
78650870682
-
Bombesin receptor-mediated imaging and cytotoxicity: review and current status
-
Sancho V., Di Florio A., Moody T.W., Jensen R.T. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv 2011, 8:79-134.
-
(2011)
Curr Drug Deliv
, vol.8
, pp. 79-134
-
-
Sancho, V.1
Di Florio, A.2
Moody, T.W.3
Jensen, R.T.4
-
83
-
-
77952091309
-
PET/CT imaging of osteoblastic bone metastases with Ga-68-bisphosphonates: first human study
-
Fellner M., Baum R.P., Kubicek V., Hermann P., Lukes I., Prasad V., et al. PET/CT imaging of osteoblastic bone metastases with Ga-68-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 2010, 37:834.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 834
-
-
Fellner, M.1
Baum, R.P.2
Kubicek, V.3
Hermann, P.4
Lukes, I.5
Prasad, V.6
-
84
-
-
35848951001
-
A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an Indium-111- or Gallium-68-labeled Affibody molecule
-
S91-S
-
Baum R.P., Orlova A., Tolmachev V., Feldwisch J. A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an Indium-111- or Gallium-68-labeled Affibody molecule. Eur J Nucl Med Mol Imaging 2006, 33. S91-S.
-
(2006)
Eur J Nucl Med Mol Imaging
, vol.33
-
-
Baum, R.P.1
Orlova, A.2
Tolmachev, V.3
Feldwisch, J.4
-
85
-
-
84862670770
-
[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH
-
Afshar-Oromieh A., Haberkorn U., Eder M., Eisenhut M., Zechmann C.M. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012, 39:1085-1086.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 1085-1086
-
-
Afshar-Oromieh, A.1
Haberkorn, U.2
Eder, M.3
Eisenhut, M.4
Zechmann, C.M.5
-
86
-
-
84861665921
-
Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors
-
Giovacchini G., Nicolas G., Forrer F. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors. Anticancer Agents Med Chem 2012, 12:526-542.
-
(2012)
Anticancer Agents Med Chem
, vol.12
, pp. 526-542
-
-
Giovacchini, G.1
Nicolas, G.2
Forrer, F.3
-
87
-
-
0024491628
-
Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin
-
Krenning E.P., Bakker W.H., Breeman W.A., Koper J.W., Kooij P.P., Ausema L., et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989, 1:242-244.
-
(1989)
Lancet
, vol.1
, pp. 242-244
-
-
Krenning, E.P.1
Bakker, W.H.2
Breeman, W.A.3
Koper, J.W.4
Kooij, P.P.5
Ausema, L.6
-
88
-
-
0027517429
-
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
-
Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
-
(1993)
Eur J Nucl Med
, vol.20
, pp. 716-731
-
-
Krenning, E.P.1
Kwekkeboom, D.J.2
Bakker, W.H.3
Breeman, W.A.4
Kooij, P.P.5
Oei, H.Y.6
-
89
-
-
28944436081
-
[123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide
-
Stahl A., Meisetschlager G., Schottelius M., Bruus-Jensen K., Wolf I., Scheidhauer K., et al. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide. Eur J Nucl Med Mol Imaging 2006, 33:45-52.
-
(2006)
Eur J Nucl Med Mol Imaging
, vol.33
, pp. 45-52
-
-
Stahl, A.1
Meisetschlager, G.2
Schottelius, M.3
Bruus-Jensen, K.4
Wolf, I.5
Scheidhauer, K.6
-
90
-
-
0036301683
-
Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy
-
Lebtahi R., Le Cloirec J., Houzard C., Daou D., Sobhani I., Sassolas G., et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med 2002, 43:889-895.
-
(2002)
J Nucl Med
, vol.43
, pp. 889-895
-
-
Lebtahi, R.1
Le Cloirec, J.2
Houzard, C.3
Daou, D.4
Sobhani, I.5
Sassolas, G.6
-
91
-
-
0141782367
-
99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study
-
Decristoforo C., Maina T., Nock B., Gabriel M., Cordopatis P., Moncayo R. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging 2003, 30:1211-1219.
-
(2003)
Eur J Nucl Med Mol Imaging
, vol.30
, pp. 1211-1219
-
-
Decristoforo, C.1
Maina, T.2
Nock, B.3
Gabriel, M.4
Cordopatis, P.5
Moncayo, R.6
-
92
-
-
0033626271
-
99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives
-
Decristoforo C., Mather S.J., Cholewinski W., Donnemiller E., Riccabona G., Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000, 27:1318-1325.
-
(2000)
Eur J Nucl Med
, vol.27
, pp. 1318-1325
-
-
Decristoforo, C.1
Mather, S.J.2
Cholewinski, W.3
Donnemiller, E.4
Riccabona, G.5
Moncayo, R.6
-
93
-
-
33747822854
-
99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience
-
Hubalewska-Dydejczyk A., Fross-Baron K., Mikolajczak R., Maecke H.R., Huszno B., Pach D., et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006, 33:1123-1133.
-
(2006)
Eur J Nucl Med Mol Imaging
, vol.33
, pp. 1123-1133
-
-
Hubalewska-Dydejczyk, A.1
Fross-Baron, K.2
Mikolajczak, R.3
Maecke, H.R.4
Huszno, B.5
Pach, D.6
-
94
-
-
0013146138
-
Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide
-
Bangard M., Behe M., Guhlke S., Otte R., Bender H., Maecke H.R., et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med 2000, 27:628-637.
-
(2000)
Eur J Nucl Med
, vol.27
, pp. 628-637
-
-
Bangard, M.1
Behe, M.2
Guhlke, S.3
Otte, R.4
Bender, H.5
Maecke, H.R.6
-
95
-
-
5444261784
-
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
-
Helisch A., Forster G.J., Reber H., Buchholz H.G., Arnold R., Goke B., et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004, 31:1386-1392.
-
(2004)
Eur J Nucl Med Mol Imaging
, vol.31
, pp. 1386-1392
-
-
Helisch, A.1
Forster, G.J.2
Reber, H.3
Buchholz, H.G.4
Arnold, R.5
Goke, B.6
-
96
-
-
49049096760
-
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG
-
Kayani I., Bomanji J.B., Groves A., Conway G., Gacinovic S., Win T., et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008, 112:2447-2455.
-
(2008)
Cancer
, vol.112
, pp. 2447-2455
-
-
Kayani, I.1
Bomanji, J.B.2
Groves, A.3
Conway, G.4
Gacinovic, S.5
Win, T.6
-
97
-
-
7344231683
-
Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide
-
Sivolapenko G.B., Skarlos D., Pectasides D., Stathopoulou E., Milonakis A., Sirmalis G., et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998, 25:1383-1389.
-
(1998)
Eur J Nucl Med
, vol.25
, pp. 1383-1389
-
-
Sivolapenko, G.B.1
Skarlos, D.2
Pectasides, D.3
Stathopoulou, E.4
Milonakis, A.5
Sirmalis, G.6
-
98
-
-
44849137859
-
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients
-
Kenny L.M., Coombes R.C., Oulie I., Contractor K.B., Miller M., Spinks T.J., et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008, 49:879-886.
-
(2008)
J Nucl Med
, vol.49
, pp. 879-886
-
-
Kenny, L.M.1
Coombes, R.C.2
Oulie, I.3
Contractor, K.B.4
Miller, M.5
Spinks, T.J.6
-
99
-
-
25444503494
-
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients
-
Beer A.J., Haubner R., Goebel M., Luderschmidt S., Spilker M.E., Wester H.J., et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005, 46:1333-1341.
-
(2005)
J Nucl Med
, vol.46
, pp. 1333-1341
-
-
Beer, A.J.1
Haubner, R.2
Goebel, M.3
Luderschmidt, S.4
Spilker, M.E.5
Wester, H.J.6
-
100
-
-
33746032220
-
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man
-
Beer A.J., Haubner R., Sarbia M., Goebel M., Luderschmidt S., Grosu A.L., et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006, 12:3942-3949.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3942-3949
-
-
Beer, A.J.1
Haubner, R.2
Sarbia, M.3
Goebel, M.4
Luderschmidt, S.5
Grosu, A.L.6
-
101
-
-
33750598987
-
Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692
-
Bach-Gansmo T., Danielsson R., Saracco A., Wilczek B., Bogsrud T.V., Fangberget A., et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006, 47:1434-1439.
-
(2006)
J Nucl Med
, vol.47
, pp. 1434-1439
-
-
Bach-Gansmo, T.1
Danielsson, R.2
Saracco, A.3
Wilczek, B.4
Bogsrud, T.V.5
Fangberget, A.6
-
102
-
-
70349234164
-
Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
-
Fröberg A.C., De Jong M., Nock B.A., Breeman W.A.P., Erion J.L., Maina T., et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009, 36:1265-1272.
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, pp. 1265-1272
-
-
Fröberg, A.C.1
De Jong, M.2
Nock, B.A.3
Breeman, W.A.P.4
Erion, J.L.5
Maina, T.6
-
103
-
-
0033754433
-
Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study
-
Van de Wiele C., Dumont F., Vanden Broecke R., Oosterlinck W., Cocquyt V., Serreyn R., et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000, 27:1694-1699.
-
(2000)
Eur J Nucl Med
, vol.27
, pp. 1694-1699
-
-
Van de Wiele, C.1
Dumont, F.2
Vanden Broecke, R.3
Oosterlinck, W.4
Cocquyt, V.5
Serreyn, R.6
-
104
-
-
38949192477
-
Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry
-
Van de Wiele C., Phonteyne P., Pauwels P., Goethals I., Van den Broecke R., Cocquyt V., et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 2008, 49:260-264.
-
(2008)
J Nucl Med
, vol.49
, pp. 260-264
-
-
Van de Wiele, C.1
Phonteyne, P.2
Pauwels, P.3
Goethals, I.4
Van den Broecke, R.5
Cocquyt, V.6
-
105
-
-
0036062011
-
Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide
-
Varvarigou A.D., Scopinaro F., Leondiadis L., Corleto V., Schillaci O., De Vincentis G., et al. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. Cancer Biother Radiopharm 2002, 17:317-326.
-
(2002)
Cancer Biother Radiopharm
, vol.17
, pp. 317-326
-
-
Varvarigou, A.D.1
Scopinaro, F.2
Leondiadis, L.3
Corleto, V.4
Schillaci, O.5
De Vincentis, G.6
-
106
-
-
0033621789
-
99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans
-
Thakur M.L., Marcus C.S., Saeed S., Pallela V., Minami C., Diggles L., et al. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med 2000, 41:107-110.
-
(2000)
J Nucl Med
, vol.41
, pp. 107-110
-
-
Thakur, M.L.1
Marcus, C.S.2
Saeed, S.3
Pallela, V.4
Minami, C.5
Diggles, L.6
-
107
-
-
0034515185
-
Imaging tumors in humans with Tc-99m-VIP
-
Thakur M.L., Marcus C.S., Saeed S., Pallela V., Minami C., Diggles L., et al. Imaging tumors in humans with Tc-99m-VIP. Ann N Y Acad Sci 2000, 921:37-44.
-
(2000)
Ann N Y Acad Sci
, vol.921
, pp. 37-44
-
-
Thakur, M.L.1
Marcus, C.S.2
Saeed, S.3
Pallela, V.4
Minami, C.5
Diggles, L.6
-
108
-
-
0031658692
-
Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer
-
Raderer M., Kurtaran A., Yang Q., Meghdadi S., Vorbeck F., Hejna M., et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med 1998, 39:1570-1575.
-
(1998)
J Nucl Med
, vol.39
, pp. 1570-1575
-
-
Raderer, M.1
Kurtaran, A.2
Yang, Q.3
Meghdadi, S.4
Vorbeck, F.5
Hejna, M.6
-
109
-
-
0033754104
-
Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours
-
Hessenius C., Bader M., Meinhold H., Bohmig M., Faiss S., Reubi J.C., et al. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. Eur J Nucl Med 2000, 27:1684-1693.
-
(2000)
Eur J Nucl Med
, vol.27
, pp. 1684-1693
-
-
Hessenius, C.1
Bader, M.2
Meinhold, H.3
Bohmig, M.4
Faiss, S.5
Reubi, J.C.6
-
110
-
-
0642310760
-
Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients
-
Buchegger F., Bonvin F., Kosinski M., Schaffland A.O., Prior J., Reubi J.C., et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003, 44:1649-1654.
-
(2003)
J Nucl Med
, vol.44
, pp. 1649-1654
-
-
Buchegger, F.1
Bonvin, F.2
Kosinski, M.3
Schaffland, A.O.4
Prior, J.5
Reubi, J.C.6
-
111
-
-
49449085799
-
Glucagon-like peptide 1-receptor scans to localize occult insulinomas
-
Wild D., Macke H., Christ E., Gloor B., Reubi J.C. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008, 359:766-768.
-
(2008)
N Engl J Med
, vol.359
, pp. 766-768
-
-
Wild, D.1
Macke, H.2
Christ, E.3
Gloor, B.4
Reubi, J.C.5
-
112
-
-
70449111654
-
Glucagon-like peptide-1 receptor imaging for localization of insulinomas
-
Christ E., Wild D., Forrer F., Brandle M., Sahli R., Clerici T., et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009, 94:4398-4405.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 4398-4405
-
-
Christ, E.1
Wild, D.2
Forrer, F.3
Brandle, M.4
Sahli, R.5
Clerici, T.6
-
113
-
-
79960296365
-
Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas
-
Wild D., Christ E., Caplin M.E., Kurzawinski T.R., Forrer F., Brandle M., et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011, 52:1073-1078.
-
(2011)
J Nucl Med
, vol.52
, pp. 1073-1078
-
-
Wild, D.1
Christ, E.2
Caplin, M.E.3
Kurzawinski, T.R.4
Forrer, F.5
Brandle, M.6
-
114
-
-
0033856992
-
Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma
-
Kwekkeboom D.J., Bakker W.H., Kooij P.P.M., Erion J., Srinivasan A., De Jong M., et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000, 27:1312-1317.
-
(2000)
Eur J Nucl Med
, vol.27
, pp. 1312-1317
-
-
Kwekkeboom, D.J.1
Bakker, W.H.2
Kooij, P.P.M.3
Erion, J.4
Srinivasan, A.5
De Jong, M.6
-
115
-
-
0242668666
-
Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies
-
Behe M., Behr T.M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002, 66:399-418.
-
(2002)
Biopolymers
, vol.66
, pp. 399-418
-
-
Behe, M.1
Behr, T.M.2
-
116
-
-
0036231110
-
Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies
-
Behr T.M., Behe M.P. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002, 32:97-109.
-
(2002)
Semin Nucl Med
, vol.32
, pp. 97-109
-
-
Behr, T.M.1
Behe, M.P.2
-
117
-
-
33750310034
-
Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma
-
Gotthardt M., Béhé M.P., Beuter D., Battmann A., Bauhofer A., Schurrat T., et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006, 33:1273-1279.
-
(2006)
Eur J Nucl Med Mol Imaging
, vol.33
, pp. 1273-1279
-
-
Gotthardt, M.1
Béhé, M.P.2
Beuter, D.3
Battmann, A.4
Bauhofer, A.5
Schurrat, T.6
-
118
-
-
33644869654
-
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
-
Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006, 24:823-834.
-
(2006)
J Clin Oncol
, vol.24
, pp. 823-834
-
-
Goldenberg, D.M.1
Sharkey, R.M.2
Paganelli, G.3
Barbet, J.4
Chatal, J.F.5
-
119
-
-
0035328530
-
Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies
-
Schuhmacher J., Kaul S., Klivenyi G., Junkermann H., Magener A., Henze M., et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 2001, 61:3712-3717.
-
(2001)
Cancer Res
, vol.61
, pp. 3712-3717
-
-
Schuhmacher, J.1
Kaul, S.2
Klivenyi, G.3
Junkermann, H.4
Magener, A.5
Henze, M.6
-
120
-
-
0034807310
-
Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET
-
Schuhmacher J., Klivenyi G., Kaul S., Henze M., Matys R., Hauser H., et al. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol 2001, 28:821-828.
-
(2001)
Nucl Med Biol
, vol.28
, pp. 821-828
-
-
Schuhmacher, J.1
Klivenyi, G.2
Kaul, S.3
Henze, M.4
Matys, R.5
Hauser, H.6
-
121
-
-
0027405124
-
Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy
-
Somasundaram C., Matzku S., Schuhmacher J., Zöller M. Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy. Cancer Immunol Immunother 1993, 36:337-345.
-
(1993)
Cancer Immunol Immunother
, vol.36
, pp. 337-345
-
-
Somasundaram, C.1
Matzku, S.2
Schuhmacher, J.3
Zöller, M.4
-
122
-
-
77957366599
-
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells
-
Rossi E.A., Rossi D.L., Stein R., Goldenberg D.M., Chang C.H. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 2010, 70:7600-7609.
-
(2010)
Cancer Res
, vol.70
, pp. 7600-7609
-
-
Rossi, E.A.1
Rossi, D.L.2
Stein, R.3
Goldenberg, D.M.4
Chang, C.H.5
-
123
-
-
48549083845
-
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
-
Sharkey R.M., Karacay H., Litwin S., Rossi E.A., McBride W.J., Chang C.H., et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008, 68:5282-5290.
-
(2008)
Cancer Res
, vol.68
, pp. 5282-5290
-
-
Sharkey, R.M.1
Karacay, H.2
Litwin, S.3
Rossi, E.A.4
McBride, W.J.5
Chang, C.H.6
-
124
-
-
1842503937
-
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates
-
Griffiths G.L., Chang C.H., McBride W.J., Rossi E.A., Sheerin A., Tejada G.R., et al. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med 2004, 45:30-39.
-
(2004)
J Nucl Med
, vol.45
, pp. 30-39
-
-
Griffiths, G.L.1
Chang, C.H.2
McBride, W.J.3
Rossi, E.A.4
Sheerin, A.5
Tejada, G.R.6
-
125
-
-
0035660907
-
Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review
-
Watine J., Miedouge M., Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis Colon Rectum 2001, 44:1791-1799.
-
(2001)
Dis Colon Rectum
, vol.44
, pp. 1791-1799
-
-
Watine, J.1
Miedouge, M.2
Friedberg, B.3
-
126
-
-
24744451447
-
Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer
-
Goldstein M.J., Mitchell E.P. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005, 23:338-351.
-
(2005)
Cancer Invest
, vol.23
, pp. 338-351
-
-
Goldstein, M.J.1
Mitchell, E.P.2
-
127
-
-
49649089800
-
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma
-
Gold D.V., Goldenberg D.M., Karacay H., Rossi E.A., Chang C.H., Cardillo T.M., et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 2008, 68:4819-4826.
-
(2008)
Cancer Res
, vol.68
, pp. 4819-4826
-
-
Gold, D.V.1
Goldenberg, D.M.2
Karacay, H.3
Rossi, E.A.4
Chang, C.H.5
Cardillo, T.M.6
-
128
-
-
33744938982
-
Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose
-
Forster G.J., Santos E.B., Smith-Jones P.M., Zanzonico P., Larson S.M. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med 2006, 47:140-149.
-
(2006)
J Nucl Med
, vol.47
, pp. 140-149
-
-
Forster, G.J.1
Santos, E.B.2
Smith-Jones, P.M.3
Zanzonico, P.4
Larson, S.M.5
-
129
-
-
42949169479
-
Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity
-
Erchegyi J., Grace C.R., Samant M., Cescato R., Piccand V., Riek R., et al. Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity. J Med Chem 2008, 51:2668-2675.
-
(2008)
J Med Chem
, vol.51
, pp. 2668-2675
-
-
Erchegyi, J.1
Grace, C.R.2
Samant, M.3
Cescato, R.4
Piccand, V.5
Riek, R.6
-
130
-
-
42949155714
-
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity
-
Grace C.R., Erchegyi J., Samant M., Cescato R., Piccand V., Riek R., et al. Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity. J Med Chem 2008, 51:2676-2681.
-
(2008)
J Med Chem
, vol.51
, pp. 2676-2681
-
-
Grace, C.R.1
Erchegyi, J.2
Samant, M.3
Cescato, R.4
Piccand, V.5
Riek, R.6
-
131
-
-
58149352876
-
Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR
-
Grace C.R., Erchegyi J., Reubi J.C., Rivier J.E., Riek R. Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR. Biopolymers 2008, 89:1077-1087.
-
(2008)
Biopolymers
, vol.89
, pp. 1077-1087
-
-
Grace, C.R.1
Erchegyi, J.2
Reubi, J.C.3
Rivier, J.E.4
Riek, R.5
-
132
-
-
46849089935
-
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting
-
Cescato R., Erchegyi J., Waser B., Piccand V., Maecke H.R., Rivier J.E., et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 2008, 51:4030-4037.
-
(2008)
J Med Chem
, vol.51
, pp. 4030-4037
-
-
Cescato, R.1
Erchegyi, J.2
Waser, B.3
Piccand, V.4
Maecke, H.R.5
Rivier, J.E.6
-
133
-
-
79851489455
-
Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors
-
Fani M., Mueller A., Tamma M.L., Nicolas G., Rink H.R., Cescato R., et al. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. J Nucl Med 2010, 51:1771-1779.
-
(2010)
J Nucl Med
, vol.51
, pp. 1771-1779
-
-
Fani, M.1
Mueller, A.2
Tamma, M.L.3
Nicolas, G.4
Rink, H.R.5
Cescato, R.6
-
134
-
-
79952656449
-
Spacer effects on in vivo properties of DOTA-conjugated dimeric [Tyr3]octreotate peptides synthesized by a "Cu(I)-click" and "sulfo-click" ligation method
-
Yim C.B., van der Wildt B., Dijkgraaf I., Joosten L., Eek A., Versluis C., et al. Spacer effects on in vivo properties of DOTA-conjugated dimeric [Tyr3]octreotate peptides synthesized by a "Cu(I)-click" and "sulfo-click" ligation method. Chembiochem 2011, 12:750-760.
-
(2011)
Chembiochem
, vol.12
, pp. 750-760
-
-
Yim, C.B.1
van der Wildt, B.2
Dijkgraaf, I.3
Joosten, L.4
Eek, A.5
Versluis, C.6
-
135
-
-
83755161916
-
Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro
-
Cescato R., Waser B., Fani M., Reubi J.C. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med 2011, 52:1886-1890.
-
(2011)
J Nucl Med
, vol.52
, pp. 1886-1890
-
-
Cescato, R.1
Waser, B.2
Fani, M.3
Reubi, J.C.4
-
136
-
-
79960323194
-
PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference
-
Fani M., Del Pozzo L., Abiraj K., Mansi R., Tamma M.L., Cescato R., et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 2011, 52:1110-1118.
-
(2011)
J Nucl Med
, vol.52
, pp. 1110-1118
-
-
Fani, M.1
Del Pozzo, L.2
Abiraj, K.3
Mansi, R.4
Tamma, M.L.5
Cescato, R.6
-
137
-
-
84866184119
-
Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications
-
Fani M., Braun F., Waser B., Beetschen K., Cescato R., Erchegyi J., et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med 2012, 53:1481-1489.
-
(2012)
J Nucl Med
, vol.53
, pp. 1481-1489
-
-
Fani, M.1
Braun, F.2
Waser, B.3
Beetschen, K.4
Cescato, R.5
Erchegyi, J.6
-
138
-
-
80052631663
-
First clinical evidence that imaging with somatostatin receptor antagonists is feasible
-
Wild D., Fani M., Behe M., Brink I., Rivier J.E., Reubi J.C., et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011, 52:1412-1417.
-
(2011)
J Nucl Med
, vol.52
, pp. 1412-1417
-
-
Wild, D.1
Fani, M.2
Behe, M.3
Brink, I.4
Rivier, J.E.5
Reubi, J.C.6
-
139
-
-
77953928471
-
The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy
-
Srirajaskanthan R., Kayani I., Quigley A.M., Soh J., Caplin M.E., Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010, 51:875-882.
-
(2010)
J Nucl Med
, vol.51
, pp. 875-882
-
-
Srirajaskanthan, R.1
Kayani, I.2
Quigley, A.M.3
Soh, J.4
Caplin, M.E.5
Bomanji, J.6
-
140
-
-
48149085905
-
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
-
Ambrosini V., Tomassetti P., Castellucci P., Campana D., Montini G., Rubello D., et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008, 35:1431-1438.
-
(2008)
Eur J Nucl Med Mol Imaging
, vol.35
, pp. 1431-1438
-
-
Ambrosini, V.1
Tomassetti, P.2
Castellucci, P.3
Campana, D.4
Montini, G.5
Rubello, D.6
-
141
-
-
79953717721
-
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine
-
Kroiss A., Putzer D., Uprimny C., Decristoforo C., Gabriel M., Santner W., et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 2011, 38:865-873.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 865-873
-
-
Kroiss, A.1
Putzer, D.2
Uprimny, C.3
Decristoforo, C.4
Gabriel, M.5
Santner, W.6
-
142
-
-
80052627039
-
68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours
-
Naji M., Zhao C., Welsh S.J., Meades R., Win Z., Ferrarese A., et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011, 13:769-775.
-
(2011)
Mol Imaging Biol
, vol.13
, pp. 769-775
-
-
Naji, M.1
Zhao, C.2
Welsh, S.J.3
Meades, R.4
Win, Z.5
Ferrarese, A.6
-
143
-
-
68249154749
-
Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-Octreotide PET in comparison to CT and bone scintigraphy
-
Putzer D., Gabriel M., Henninger B., Kendler D., Uprimny C., Dobrozemsky G., et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-Octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009, 50:1214-1221.
-
(2009)
J Nucl Med
, vol.50
, pp. 1214-1221
-
-
Putzer, D.1
Gabriel, M.2
Henninger, B.3
Kendler, D.4
Uprimny, C.5
Dobrozemsky, G.6
-
144
-
-
84865485341
-
Nuclear medicine imaging of neuroendocrine tumours
-
Al-Nahhas A. Nuclear medicine imaging of neuroendocrine tumours. Clin Med 2012, 12:377-380.
-
(2012)
Clin Med
, vol.12
, pp. 377-380
-
-
Al-Nahhas, A.1
-
145
-
-
84860008181
-
PET/CT imaging in different types of lung cancer: an overview
-
Ambrosini V., Nicolini S., Caroli P., Nanni C., Massaro A., Marzola M.C., et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol 2012, 81:988-1001.
-
(2012)
Eur J Radiol
, vol.81
, pp. 988-1001
-
-
Ambrosini, V.1
Nicolini, S.2
Caroli, P.3
Nanni, C.4
Massaro, A.5
Marzola, M.C.6
-
146
-
-
84865297450
-
(6)(8)Ga-labelled peptides for diagnosis of gastroenteropancreatic NET
-
Ambrosini V., Campana D., Tomassetti P., Fanti S. (6)(8)Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 2012, 39(Suppl 1):S52-S60.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, Issue.SUPPL.1
-
-
Ambrosini, V.1
Campana, D.2
Tomassetti, P.3
Fanti, S.4
-
147
-
-
84925581799
-
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy
-
Oberg K.E., Reubi J.C., Kwekkeboom D.J., Krenning E.P. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010, 139(742-53):53 e1.
-
(2010)
Gastroenterology
, vol.139
, Issue.53-742
-
-
Oberg, K.E.1
Reubi, J.C.2
Kwekkeboom, D.J.3
Krenning, E.P.4
-
148
-
-
84857274407
-
High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
-
Hofman M.S., Kong G., Neels O.C., Eu P., Hong E., Hicks R.J. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 2012, 56:40-47.
-
(2012)
J Med Imaging Radiat Oncol
, vol.56
, pp. 40-47
-
-
Hofman, M.S.1
Kong, G.2
Neels, O.C.3
Eu, P.4
Hong, E.5
Hicks, R.J.6
-
149
-
-
84858114170
-
Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET
-
Jacobsson H., Larsson P., Jonsson C., Jussing E., Gryback P. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med 2012, 37:362-365.
-
(2012)
Clin Nucl Med
, vol.37
, pp. 362-365
-
-
Jacobsson, H.1
Larsson, P.2
Jonsson, C.3
Jussing, E.4
Gryback, P.5
-
150
-
-
79961081889
-
Exploring new frontiers in molecular imaging: emergence of Ga PET/CT
-
Tan E.H., Goh S.W. Exploring new frontiers in molecular imaging: emergence of Ga PET/CT. World J Radiol 2010, 2:55-67.
-
(2010)
World J Radiol
, vol.2
, pp. 55-67
-
-
Tan, E.H.1
Goh, S.W.2
-
151
-
-
84865279631
-
(6)(8)Ga-labelled peptides in the management of neuroectodermal tumours
-
AL-N.A.
-
Naji M., AL-N.A. (6)(8)Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging 2012, 39(Suppl 1):S61-S67.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, Issue.SUPPL.1
-
-
Naji, M.1
-
152
-
-
84865471278
-
Comparison of (68)Ga-DOTATATE and (68)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours
-
Kabasakal L., Demirci E., Ocak M., Decristoforo C., Araman A., Ozsoy Y., et al. Comparison of (68)Ga-DOTATATE and (68)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012, 39(8):1271-1277.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, Issue.8
, pp. 1271-1277
-
-
Kabasakal, L.1
Demirci, E.2
Ocak, M.3
Decristoforo, C.4
Araman, A.5
Ozsoy, Y.6
-
153
-
-
79851501287
-
Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC
-
Zhang H., Moroz M.A., Serganova I., Ku T., Huang R., Vider J., et al. Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC. J Nucl Med 2011, 52:123-131.
-
(2011)
J Nucl Med
, vol.52
, pp. 123-131
-
-
Zhang, H.1
Moroz, M.A.2
Serganova, I.3
Ku, T.4
Huang, R.5
Vider, J.6
-
154
-
-
84862829823
-
Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE
-
Velikyan I., Xu H., Nair M., Hall H. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol 2012, 39:628-659.
-
(2012)
Nucl Med Biol
, vol.39
, pp. 628-659
-
-
Velikyan, I.1
Xu, H.2
Nair, M.3
Hall, H.4
-
155
-
-
83755171298
-
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors
-
Poeppel T.D., Binse I., Petersenn S., Lahner H., Schott M., Antoch G., et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011, 52:1864-1870.
-
(2011)
J Nucl Med
, vol.52
, pp. 1864-1870
-
-
Poeppel, T.D.1
Binse, I.2
Petersenn, S.3
Lahner, H.4
Schott, M.5
Antoch, G.6
-
156
-
-
77952510479
-
Preliminary experience with Ga-68-DOTA-lanreotide positron emission tomography
-
Traub-Weidinger T., Von Guggenberg E., Dobrozemsky G., Kendler D., Eisterer W., Bale R., et al. Preliminary experience with Ga-68-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging 2010, 54:52-60.
-
(2010)
Q J Nucl Med Mol Imaging
, vol.54
, pp. 52-60
-
-
Traub-Weidinger, T.1
Von Guggenberg, E.2
Dobrozemsky, G.3
Kendler, D.4
Eisterer, W.5
Bale, R.6
-
157
-
-
84864542705
-
Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs)
-
Oberg K. Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2012, 2:448-458.
-
(2012)
Theranostics
, vol.2
, pp. 448-458
-
-
Oberg, K.1
-
158
-
-
71549154678
-
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
-
Gehler B., Paulsen F., Oksuz M.O., Hauser T.K., Eschmann S.M., Bares R., et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol 2009, 4:56.
-
(2009)
Radiat Oncol
, vol.4
, pp. 56
-
-
Gehler, B.1
Paulsen, F.2
Oksuz, M.O.3
Hauser, T.K.4
Eschmann, S.M.5
Bares, R.6
-
159
-
-
33646005789
-
Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET
-
Milker-Zabel S., Zabel-du Bois A., Henze M., Huber P., Schulz-Ertner D., Hoess A., et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006, 65:222-227.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.65
, pp. 222-227
-
-
Milker-Zabel, S.1
Zabel-du Bois, A.2
Henze, M.3
Huber, P.4
Schulz-Ertner, D.5
Hoess, A.6
-
160
-
-
77952487451
-
Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients
-
Gabriel M., Andergassen U., Putzer D., Kroiss A., Waitz D., Von Guggenberg E., et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010, 54:92-99.
-
(2010)
Q J Nucl Med Mol Imaging
, vol.54
, pp. 92-99
-
-
Gabriel, M.1
Andergassen, U.2
Putzer, D.3
Kroiss, A.4
Waitz, D.5
Von Guggenberg, E.6
-
161
-
-
77952519078
-
Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients
-
Putzer D., Gabriel M., Kendler D., Henninger B., Knoflach M., Kroiss A., et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010, 54:68-75.
-
(2010)
Q J Nucl Med Mol Imaging
, vol.54
, pp. 68-75
-
-
Putzer, D.1
Gabriel, M.2
Kendler, D.3
Henninger, B.4
Knoflach, M.5
Kroiss, A.6
-
162
-
-
34147093265
-
68Ga-DOTATATE PET in neuroectodermal tumours: first experience
-
Win Z., Al-Nahhas A., Towey D., Todd J.F., Rubello D., Lewington V., et al. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007, 28:359-363.
-
(2007)
Nucl Med Commun
, vol.28
, pp. 359-363
-
-
Win, Z.1
Al-Nahhas, A.2
Towey, D.3
Todd, J.F.4
Rubello, D.5
Lewington, V.6
-
163
-
-
77952503305
-
Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions
-
Prasad V., Baum R.P. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 2010, 54:61-67.
-
(2010)
Q J Nucl Med Mol Imaging
, vol.54
, pp. 61-67
-
-
Prasad, V.1
Baum, R.P.2
-
164
-
-
77952095222
-
Ga-68-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours
-
Ambrosini V., Nanni C., Zompatori M., Campana D., Tomassetti P., Castellucci P., et al. Ga-68-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010, 37:722-727.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 722-727
-
-
Ambrosini, V.1
Nanni, C.2
Zompatori, M.3
Campana, D.4
Tomassetti, P.5
Castellucci, P.6
-
165
-
-
77957096107
-
68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. Journal of nuclear medicine: official publication
-
Haug A.R., Auernhammer C.J., Wangler B., Schmidt G.P., Uebleis C., Goke B., et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. Journal of nuclear medicine: official publication. Soc Nucl Med 2010, 51:1349-1356.
-
(2010)
Soc Nucl Med
, vol.51
, pp. 1349-1356
-
-
Haug, A.R.1
Auernhammer, C.J.2
Wangler, B.3
Schmidt, G.P.4
Uebleis, C.5
Goke, B.6
-
166
-
-
78349282294
-
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors
-
Frilling A., Sotiropoulos G.C., Radtke A., Malago M., Bockisch A., Kuehl H., et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010, 252:850-856.
-
(2010)
Ann Surg
, vol.252
, pp. 850-856
-
-
Frilling, A.1
Sotiropoulos, G.C.2
Radtke, A.3
Malago, M.4
Bockisch, A.5
Kuehl, H.6
-
167
-
-
77951259729
-
Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study
-
Versari A., Camellini L., Carlinfante G., Frasoldati A., Nicoli F., Grassi E., et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010, 35:321-328.
-
(2010)
Clin Nucl Med
, vol.35
, pp. 321-328
-
-
Versari, A.1
Camellini, L.2
Carlinfante, G.3
Frasoldati, A.4
Nicoli, F.5
Grassi, E.6
-
168
-
-
59649092454
-
Ga-68 DOTATOC PET/CT changed the therapeutic course of a patient with the sudden onset of vision problems
-
Van Riet J., Rattat D., Verbruggen A., Mortelmans L., Mottaghy F.M. Ga-68 DOTATOC PET/CT changed the therapeutic course of a patient with the sudden onset of vision problems. Clin Nucl Med 2009, 34:27-28.
-
(2009)
Clin Nucl Med
, vol.34
, pp. 27-28
-
-
Van Riet, J.1
Rattat, D.2
Verbruggen, A.3
Mortelmans, L.4
Mottaghy, F.M.5
-
169
-
-
84872117156
-
Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia
-
Froeling V., Elgeti F., Maurer M.H., Scheurig-Muenkler C., Beck A., Kroencke T.J., et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med 2012, 26:738-743.
-
(2012)
Ann Nucl Med
, vol.26
, pp. 738-743
-
-
Froeling, V.1
Elgeti, F.2
Maurer, M.H.3
Scheurig-Muenkler, C.4
Beck, A.5
Kroencke, T.J.6
-
170
-
-
84858737611
-
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
-
Beauregard J.M., Hofman M.S., Kong G., Hicks R.J. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2012, 39:50-56.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 50-56
-
-
Beauregard, J.M.1
Hofman, M.S.2
Kong, G.3
Hicks, R.J.4
-
171
-
-
84865453781
-
Is (6)(8)Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
-
Ambrosini V., Campana D., Nanni C., Cambioli S., Tomassetti P., Rubello D., et al. Is (6)(8)Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. Eur J Nucl Med Mol Imaging 2012, 39:1278-1283.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 1278-1283
-
-
Ambrosini, V.1
Campana, D.2
Nanni, C.3
Cambioli, S.4
Tomassetti, P.5
Rubello, D.6
-
172
-
-
75149152486
-
Pancreatic neuroendocrine tumor with involvement of the inferior mesenteric vein diagnosed by Ga-68 DOTA-TATE PET/CT
-
Sainz-Esteban A., Prasad V., Baum R.P. Pancreatic neuroendocrine tumor with involvement of the inferior mesenteric vein diagnosed by Ga-68 DOTA-TATE PET/CT. Clin Nucl Med 2010, 35:40-41.
-
(2010)
Clin Nucl Med
, vol.35
, pp. 40-41
-
-
Sainz-Esteban, A.1
Prasad, V.2
Baum, R.P.3
-
173
-
-
80052044503
-
Use of Ga-68 DOTATATE PET/CT to confirm portal vein tumor thrombosis in a patient with pancreatic neuroendocrine tumor
-
Lim T.C., Tan E.H., Zaheer S. Use of Ga-68 DOTATATE PET/CT to confirm portal vein tumor thrombosis in a patient with pancreatic neuroendocrine tumor. Clin Nucl Med 2011, 36:498-499.
-
(2011)
Clin Nucl Med
, vol.36
, pp. 498-499
-
-
Lim, T.C.1
Tan, E.H.2
Zaheer, S.3
-
174
-
-
79953049249
-
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease
-
Ambrosini V., Campana D., Allegri V., Opocher G., Fanti S. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. Clin Nucl Med 2011, 36:64-65.
-
(2011)
Clin Nucl Med
, vol.36
, pp. 64-65
-
-
Ambrosini, V.1
Campana, D.2
Allegri, V.3
Opocher, G.4
Fanti, S.5
-
175
-
-
84864838491
-
Imaging carotid body chemodectomas with (6)(8)Ga-DOTA-NOC PET-CT
-
Naswa N., Kumar A., Sharma P., Bal C., Malhotra A., Kumar R. Imaging carotid body chemodectomas with (6)(8)Ga-DOTA-NOC PET-CT. Br J Radiol 2012, 85:1140-1145.
-
(2012)
Br J Radiol
, vol.85
, pp. 1140-1145
-
-
Naswa, N.1
Kumar, A.2
Sharma, P.3
Bal, C.4
Malhotra, A.5
Kumar, R.6
-
176
-
-
78651311176
-
68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results
-
Ambrosini V., Zompatori M., De Luca F., Antonia D.E., Allegri V., Nanni C., et al. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med 2010, 51:1950-1955.
-
(2010)
J Nucl Med
, vol.51
, pp. 1950-1955
-
-
Ambrosini, V.1
Zompatori, M.2
De Luca, F.3
Antonia, D.E.4
Allegri, V.5
Nanni, C.6
-
177
-
-
84861437736
-
68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone level
-
Nicolini S., Ambrosini V., Fantini L., Fanti S. 68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone level. Clin Nucl Med 2012, 37:591-592.
-
(2012)
Clin Nucl Med
, vol.37
, pp. 591-592
-
-
Nicolini, S.1
Ambrosini, V.2
Fantini, L.3
Fanti, S.4
-
178
-
-
84855209759
-
Alveolar rhabdomyosarcoma with neuroendocrine differentiation detected by Ga-68 DOTA-NOC PET/CT: a case report
-
Zanoni L., Lopci E., Ambrosini V., Boschi S., Fanti S. Alveolar rhabdomyosarcoma with neuroendocrine differentiation detected by Ga-68 DOTA-NOC PET/CT: a case report. Clin Nucl Med 2011, 36:915-918.
-
(2011)
Clin Nucl Med
, vol.36
, pp. 915-918
-
-
Zanoni, L.1
Lopci, E.2
Ambrosini, V.3
Boschi, S.4
Fanti, S.5
-
179
-
-
66749191443
-
Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies
-
Lincke T., Singer J., Kluge R., Sabri O., Paschke R. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Thyroid 2009, 19:381-389.
-
(2009)
Thyroid
, vol.19
, pp. 381-389
-
-
Lincke, T.1
Singer, J.2
Kluge, R.3
Sabri, O.4
Paschke, R.5
-
180
-
-
77149129036
-
Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT
-
Luboldt W., Zophel K., Wunderlich G., Abramyuk A., Luboldt H.J., Kotzerke J. Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. Mol Imaging Biol 2010, 12:78-84.
-
(2010)
Mol Imaging Biol
, vol.12
, pp. 78-84
-
-
Luboldt, W.1
Zophel, K.2
Wunderlich, G.3
Abramyuk, A.4
Luboldt, H.J.5
Kotzerke, J.6
-
181
-
-
77956216707
-
Hybrid PET/MRI of Intracranial Masses: Initial Experiences and Comparison to PET/CT
-
Boss A., Bisdas S., Kolb A., Hofmann M., Ernemann U., Claussen C.D., et al. Hybrid PET/MRI of Intracranial Masses: Initial Experiences and Comparison to PET/CT. J Nucl Med 2010, 51:1198-1205.
-
(2010)
J Nucl Med
, vol.51
, pp. 1198-1205
-
-
Boss, A.1
Bisdas, S.2
Kolb, A.3
Hofmann, M.4
Ernemann, U.5
Claussen, C.D.6
-
182
-
-
72949103236
-
Comparison of Ga-68-DOTATATE and F-18-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma
-
Conry B.G., Papathanasiou N.D., Prakash V., Kayani I., Caplin M., Mahmood S., et al. Comparison of Ga-68-DOTATATE and F-18-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010, 37:49-57.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 49-57
-
-
Conry, B.G.1
Papathanasiou, N.D.2
Prakash, V.3
Kayani, I.4
Caplin, M.5
Mahmood, S.6
-
183
-
-
75749100662
-
In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors
-
Rominger A., Saam T., Vogl E., Ubleis C., la Fougere C., Forster S., et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med 2010, 51:193-197.
-
(2010)
J Nucl Med
, vol.51
, pp. 193-197
-
-
Rominger, A.1
Saam, T.2
Vogl, E.3
Ubleis, C.4
la Fougere, C.5
Forster, S.6
-
184
-
-
80051778032
-
Tc-99m- and Ga-68-labeled somatostatin analogues in the evaluation of Hurthle cell thyroid cancer
-
Gambini J.P., Quagliata A., Finozzi R., Serra P., Lago G., Gaudiano J., et al. Tc-99m- and Ga-68-labeled somatostatin analogues in the evaluation of Hurthle cell thyroid cancer. Clin Nucl Med 2011, 36:803-804.
-
(2011)
Clin Nucl Med
, vol.36
, pp. 803-804
-
-
Gambini, J.P.1
Quagliata, A.2
Finozzi, R.3
Serra, P.4
Lago, G.5
Gaudiano, J.6
-
185
-
-
78649332447
-
Distribution pattern of Ga-68-DOTATATE in disease-free patients
-
Shastry M., Kayani I., Wild D., Caplin M., Visvikis D., Gacinovic S., et al. Distribution pattern of Ga-68-DOTATATE in disease-free patients. Nucl Med Commun 2010, 31:1025-1032.
-
(2010)
Nucl Med Commun
, vol.31
, pp. 1025-1032
-
-
Shastry, M.1
Kayani, I.2
Wild, D.3
Caplin, M.4
Visvikis, D.5
Gacinovic, S.6
-
186
-
-
80255138228
-
Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
-
Al-Ibraheem A., Bundschuh R.A., Notni J., Buck A., Winter A., Wester H.J., et al. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?. Eur J Nucl Med Mol Imaging 2011, 38:2005-2013.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 2005-2013
-
-
Al-Ibraheem, A.1
Bundschuh, R.A.2
Notni, J.3
Buck, A.4
Winter, A.5
Wester, H.J.6
-
187
-
-
79958124607
-
Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT
-
Castellucci P., Pou Ucha J., Fuccio C., Rubello D., Ambrosini V., Montini G.C., et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 2011, 52:886-890.
-
(2011)
J Nucl Med
, vol.52
, pp. 886-890
-
-
Castellucci, P.1
Pou Ucha, J.2
Fuccio, C.3
Rubello, D.4
Ambrosini, V.5
Montini, G.C.6
-
188
-
-
84856436096
-
Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns
-
Krausz Y., Rubinstein R., Appelbaum L., Mishani E., Orevi M., Fraenkel M., et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med 2012, 37:57-62.
-
(2012)
Clin Nucl Med
, vol.37
, pp. 57-62
-
-
Krausz, Y.1
Rubinstein, R.2
Appelbaum, L.3
Mishani, E.4
Orevi, M.5
Fraenkel, M.6
-
189
-
-
79953721154
-
Wandering spleen on a 68Ga-DOTATOC-PET/CT scan
-
Lips N., Deroose C.M., Bielen D., Bossuyt P., Mortelmans L. Wandering spleen on a 68Ga-DOTATOC-PET/CT scan. Eur J Nucl Med Mol Imaging 2011, 38:982.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 982
-
-
Lips, N.1
Deroose, C.M.2
Bielen, D.3
Bossuyt, P.4
Mortelmans, L.5
-
190
-
-
77950345549
-
Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors
-
Campana D., Ambrosini V., Pezzilli R., Fanti S., Labate A.M.M., Santini D., et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010, 51:353-359.
-
(2010)
J Nucl Med
, vol.51
, pp. 353-359
-
-
Campana, D.1
Ambrosini, V.2
Pezzilli, R.3
Fanti, S.4
Labate, A.M.M.5
Santini, D.6
-
191
-
-
79958046632
-
68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax
-
Boy C., Heusner T.A., Poeppel T.D., Redmann-Bischofs A., Unger N., Jentzen W., et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011, 38:1224-1236.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 1224-1236
-
-
Boy, C.1
Heusner, T.A.2
Poeppel, T.D.3
Redmann-Bischofs, A.4
Unger, N.5
Jentzen, W.6
-
192
-
-
80455127123
-
Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors
-
Haug A.R., Rominger A., Mustafa M., Auernhammer C., Goke B., Schmidt G.P., et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011, 52:1679-1683.
-
(2011)
J Nucl Med
, vol.52
, pp. 1679-1683
-
-
Haug, A.R.1
Rominger, A.2
Mustafa, M.3
Auernhammer, C.4
Goke, B.5
Schmidt, G.P.6
-
193
-
-
0036892174
-
Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of Indium-111 Octreotide
-
Stokkel M.P.M., Boot I.N., Smit J.W. Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of Indium-111 Octreotide. Q J Nucl Med 2002, 46:331-335.
-
(2002)
Q J Nucl Med
, vol.46
, pp. 331-335
-
-
Stokkel, M.P.M.1
Boot, I.N.2
Smit, J.W.3
-
194
-
-
80455164737
-
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: Which is a better therapy option?
-
Kunikowska J., Królicki L., Hubalewska-Dydejczyk A., Mikolajczak R., Sowa-Staszczak A., Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: Which is a better therapy option?. Eur J Nucl Med Mol Imaging 2011, 38:1788-1797.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 1788-1797
-
-
Kunikowska, J.1
Królicki, L.2
Hubalewska-Dydejczyk, A.3
Mikolajczak, R.4
Sowa-Staszczak, A.5
Pawlak, D.6
-
195
-
-
17944362339
-
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients
-
Kwekkeboom D.J., Bakker W.H., Kooij P.P., Konijnenberg M.W., Srinivasan A., Erion J.L., et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001, 28:1319-1325.
-
(2001)
Eur J Nucl Med
, vol.28
, pp. 1319-1325
-
-
Kwekkeboom, D.J.1
Bakker, W.H.2
Kooij, P.P.3
Konijnenberg, M.W.4
Srinivasan, A.5
Erion, J.L.6
-
197
-
-
0033624196
-
In situ radiotherapy with 111In-pentetreotide: State of the art and perspectives
-
McCarthy K.E., Woltering E.A., Anthony L.B. In situ radiotherapy with 111In-pentetreotide: State of the art and perspectives. Q J Nucl Med 2000, 44:88-95.
-
(2000)
Q J Nucl Med
, vol.44
, pp. 88-95
-
-
McCarthy, K.E.1
Woltering, E.A.2
Anthony, L.B.3
-
198
-
-
33947271518
-
Neuroendocrine tumors. Peptide receptor radionuclide therapy
-
Forrer F., Valkema R., Kwekkeboom D.J., de Jong M., Krenning E.P. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007, 21:111-129.
-
(2007)
Best Pract Res Clin Endocrinol Metab
, vol.21
, pp. 111-129
-
-
Forrer, F.1
Valkema, R.2
Kwekkeboom, D.J.3
de Jong, M.4
Krenning, E.P.5
-
199
-
-
84867048375
-
The bad berka dose protocol: Comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC
-
Schuchardt C., Kulkarni H.R., Prasad V., Zachert C., Müller D., Baum R.P. The bad berka dose protocol: Comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC. Recent Results Cancer Res 2013, 194:519-536.
-
(2013)
Recent Results Cancer Res
, vol.194
, pp. 519-536
-
-
Schuchardt, C.1
Kulkarni, H.R.2
Prasad, V.3
Zachert, C.4
Müller, D.5
Baum, R.P.6
-
200
-
-
84859647808
-
Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy
-
Sainz-Esteban A., Prasad V., Schuchardt C., Zachert C., Carril J.M., Baum R.P. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2012, 39:501-511.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 501-511
-
-
Sainz-Esteban, A.1
Prasad, V.2
Schuchardt, C.3
Zachert, C.4
Carril, J.M.5
Baum, R.P.6
-
201
-
-
0030737659
-
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy
-
Otte A., Jermann E., Behe M., Goetze M., Bucher H.C., Roser H.W., et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997, 24:792-795.
-
(1997)
Eur J Nucl Med
, vol.24
, pp. 792-795
-
-
Otte, A.1
Jermann, E.2
Behe, M.3
Goetze, M.4
Bucher, H.C.5
Roser, H.W.6
-
202
-
-
0036231005
-
111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial
-
Virgolini I., Britton K., Buscombe J., Moncayo R., Paganelli G., Riva P. 111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002, 32:148-155.
-
(2002)
Semin Nucl Med
, vol.32
, pp. 148-155
-
-
Virgolini, I.1
Britton, K.2
Buscombe, J.3
Moncayo, R.4
Paganelli, G.5
Riva, P.6
-
203
-
-
84855759431
-
Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study
-
Kaemmerer D., Prasad V., Daffner W., Haugvik S.P., Senftleben S., Baum R.P., et al. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin Nucl Med 2012, 37:142-147.
-
(2012)
Clin Nucl Med
, vol.37
, pp. 142-147
-
-
Kaemmerer, D.1
Prasad, V.2
Daffner, W.3
Haugvik, S.P.4
Senftleben, S.5
Baum, R.P.6
-
204
-
-
57349195981
-
Peptide-based probes for cancer imaging
-
Reubi J.C., Maecke H.R. Peptide-based probes for cancer imaging. J Nucl Med 2008, 49:1735-1738.
-
(2008)
J Nucl Med
, vol.49
, pp. 1735-1738
-
-
Reubi, J.C.1
Maecke, H.R.2
-
205
-
-
83655191987
-
Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy
-
Waser B., Beetschen K., Pellegata N.S., Reubi J.C. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 2011, 94:291-301.
-
(2011)
Neuroendocrinology
, vol.94
, pp. 291-301
-
-
Waser, B.1
Beetschen, K.2
Pellegata, N.S.3
Reubi, J.C.4
-
206
-
-
44249128244
-
Bombesin receptor imaging in various tumors: first results of Ga-68 AMBA PET/CT
-
S193-S
-
Baum R.P., Prasad V., Frischknecht M., Maecke H., Reubi J. Bombesin receptor imaging in various tumors: first results of Ga-68 AMBA PET/CT. Eur J Nucl Med Mol Imaging 2007, 34. S193-S.
-
(2007)
Eur J Nucl Med Mol Imaging
, vol.34
-
-
Baum, R.P.1
Prasad, V.2
Frischknecht, M.3
Maecke, H.4
Reubi, J.5
-
207
-
-
77956431127
-
Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA
-
Cagnolini A., Chen J., Ramos K., Skedzielewski T.M., Lantry L.E., Nunn A.D., et al. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA. Appl Radiat Isot 2010, 68:2285-2292.
-
(2010)
Appl Radiat Isot
, vol.68
, pp. 2285-2292
-
-
Cagnolini, A.1
Chen, J.2
Ramos, K.3
Skedzielewski, T.M.4
Lantry, L.E.5
Nunn, A.D.6
-
208
-
-
84866784727
-
Sc-44-DOTA-BN 2-14 NH2 in comparison to Ga-68-DOTA-BN 2-14 NH2 in pre-clinical investigation. Is Sc-44 a potential radionuclide for PET?
-
Koumarianou E., Loktionova N.S., Fellner M., Roesch F., Thews O., Pawlak D., et al. Sc-44-DOTA-BN 2-14 NH2 in comparison to Ga-68-DOTA-BN 2-14 NH2 in pre-clinical investigation. Is Sc-44 a potential radionuclide for PET?. Appl Radiat Isot 2012, 70:2669-2676.
-
(2012)
Appl Radiat Isot
, vol.70
, pp. 2669-2676
-
-
Koumarianou, E.1
Loktionova, N.S.2
Fellner, M.3
Roesch, F.4
Thews, O.5
Pawlak, D.6
-
209
-
-
79551589409
-
Pharmacokinetic studies of 68Ga-labeled bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results
-
Dimitrakopoulou-Strauss A., Seiz M., Tuettenberg J., Schmieder K., Eisenhut M., Haberkorn U., et al. Pharmacokinetic studies of 68Ga-labeled bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med 2011, 36:101-108.
-
(2011)
Clin Nucl Med
, vol.36
, pp. 101-108
-
-
Dimitrakopoulou-Strauss, A.1
Seiz, M.2
Tuettenberg, J.3
Schmieder, K.4
Eisenhut, M.5
Haberkorn, U.6
-
210
-
-
12444338751
-
Feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients
-
S253-S
-
Hofmann M., Machtens S., Stief C., Langer F., Boerner A.R., Maecke H., et al. Feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients. Eur J Nucl Med Mol Imaging 2004, 31. S253-S.
-
(2004)
Eur J Nucl Med Mol Imaging
, vol.31
-
-
Hofmann, M.1
Machtens, S.2
Stief, C.3
Langer, F.4
Boerner, A.R.5
Maecke, H.6
-
211
-
-
84875745842
-
Glucagon-like peptide-1 receptor imaging with [Lys 40(Ahx-HYNIC- 99mTc/EDDA)NH 2]-exendin-4 for the detection of insulinoma
-
Sowa-Staszczak A., Pach D., Mikołajczak R., Mäcke H., Jabrocka-Hybel A., Stefańska A., et al. Glucagon-like peptide-1 receptor imaging with [Lys 40(Ahx-HYNIC- 99mTc/EDDA)NH 2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 2013, 40(4):524-531.
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, Issue.4
, pp. 524-531
-
-
Sowa-Staszczak, A.1
Pach, D.2
Mikołajczak, R.3
Mäcke, H.4
Jabrocka-Hybel, A.5
Stefańska, A.6
-
212
-
-
80455129812
-
PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent
-
Gourni E., Demmer O., Schottelius M., D'Alessandria C., Schulz S., Dijkgraaf I., et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med 2011, 52:1803-1810.
-
(2011)
J Nucl Med
, vol.52
, pp. 1803-1810
-
-
Gourni, E.1
Demmer, O.2
Schottelius, M.3
D'Alessandria, C.4
Schulz, S.5
Dijkgraaf, I.6
-
213
-
-
80455162590
-
Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4
-
Demmer O., Dijkgraaf I., Schumacher U., Marinelli L., Cosconati S., Gourni E., et al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem 2011, 54:7648-7662.
-
(2011)
J Med Chem
, vol.54
, pp. 7648-7662
-
-
Demmer, O.1
Dijkgraaf, I.2
Schumacher, U.3
Marinelli, L.4
Cosconati, S.5
Gourni, E.6
-
214
-
-
80053432658
-
PET imaging of CXCR4 receptors in cancer by a new optimized ligand
-
Demmer O., Gourni E., Schumacher U., Kessler H., Wester H.J. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem 2011, 6(2):1789-1791.
-
(2011)
ChemMedChem
, vol.6
, Issue.2
, pp. 1789-1791
-
-
Demmer, O.1
Gourni, E.2
Schumacher, U.3
Kessler, H.4
Wester, H.J.5
-
215
-
-
84857030157
-
Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression
-
Hennrich U., Seyler L., Schafer M., Bauder-Wust U., Eisenhut M., Semmler W., et al. Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression. Bioorg Med Chem 2012, 20:1502-1510.
-
(2012)
Bioorg Med Chem
, vol.20
, pp. 1502-1510
-
-
Hennrich, U.1
Seyler, L.2
Schafer, M.3
Bauder-Wust, U.4
Eisenhut, M.5
Semmler, W.6
-
216
-
-
45749140130
-
Development of novel Ga-68- and F-18-labeled GnRH-I analogues with high GnRHR-targeting efficiency
-
Schottelius M., Berger S., Poethko T., Schwaiger M., Wester H.J. Development of novel Ga-68- and F-18-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconjug Chem 2008, 19:1256-1268.
-
(2008)
Bioconjug Chem
, vol.19
, pp. 1256-1268
-
-
Schottelius, M.1
Berger, S.2
Poethko, T.3
Schwaiger, M.4
Wester, H.J.5
-
217
-
-
47049103644
-
Introduction of functional groups into peptides via N-alkylation
-
Demmer O., Dijkgraaf I., Schottelius M., Wester H.J., Kessler H. Introduction of functional groups into peptides via N-alkylation. Organic Lett 2008, 10:2015-2018.
-
(2008)
Organic Lett
, vol.10
, pp. 2015-2018
-
-
Demmer, O.1
Dijkgraaf, I.2
Schottelius, M.3
Wester, H.J.4
Kessler, H.5
-
218
-
-
67349235942
-
Development of high-specific-activity Ga-68-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors
-
Cantorias M.V., Figueroa S.D., Quinn T.P., Lever J.R., Hoffman T.J., Watkinson L.D., et al. Development of high-specific-activity Ga-68-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol 2009, 36:505-513.
-
(2009)
Nucl Med Biol
, vol.36
, pp. 505-513
-
-
Cantorias, M.V.1
Figueroa, S.D.2
Quinn, T.P.3
Lever, J.R.4
Hoffman, T.J.5
Watkinson, L.D.6
-
219
-
-
35848944660
-
Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma
-
Wei L., Miao Y., Gallazzi F., Quinn T.P., Welch M.J., Vavere A.L., et al. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol 2007, 34:945-953.
-
(2007)
Nucl Med Biol
, vol.34
, pp. 945-953
-
-
Wei, L.1
Miao, Y.2
Gallazzi, F.3
Quinn, T.P.4
Welch, M.J.5
Vavere, A.L.6
-
220
-
-
80052604141
-
Improved synthesis and biological evaluation of chelator-modified alpha-MSH analogs prepared by copper-free click chemistry
-
Baumhover N.J., Martin M.E., Parameswarappa S.G., Kloepping K.C., O'Dorisio M.S., Pigge F.C., et al. Improved synthesis and biological evaluation of chelator-modified alpha-MSH analogs prepared by copper-free click chemistry. Bioorg Med Chem Lett 2011, 21:5757-5761.
-
(2011)
Bioorg Med Chem Lett
, vol.21
, pp. 5757-5761
-
-
Baumhover, N.J.1
Martin, M.E.2
Parameswarappa, S.G.3
Kloepping, K.C.4
O'Dorisio, M.S.5
Pigge, F.C.6
-
221
-
-
84862705209
-
Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake
-
Guo H., Gallazzi F., Miao Y. Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake. Bioconjug Chem 2012, 23:1341-1348.
-
(2012)
Bioconjug Chem
, vol.23
, pp. 1341-1348
-
-
Guo, H.1
Gallazzi, F.2
Miao, Y.3
-
222
-
-
1842592125
-
A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases
-
Froidevaux S., Calame-Christe M., Schuhmacher J., Tanner H., Saffrich R., Henze M., et al. A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004, 45:116-123.
-
(2004)
J Nucl Med
, vol.45
, pp. 116-123
-
-
Froidevaux, S.1
Calame-Christe, M.2
Schuhmacher, J.3
Tanner, H.4
Saffrich, R.5
Henze, M.6
-
223
-
-
77951474500
-
Biodistribution of 89 Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer
-
Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., De Jong J.R., et al. Biodistribution of 89 Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87:586-592.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 586-592
-
-
Dijkers, E.C.1
Oude Munnink, T.H.2
Kosterink, J.G.3
Brouwers, A.H.4
Jager, P.L.5
De Jong, J.R.6
-
224
-
-
33744831505
-
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
-
Perik P.J., Lub-De Hooge M.N., Gietema J.A., Van Der Graaf W.T.A., De Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2276-2282
-
-
Perik, P.J.1
Lub-De Hooge, M.N.2
Gietema, J.A.3
Van Der Graaf, W.T.A.4
De Korte, M.A.5
Jonkman, S.6
-
225
-
-
77953927395
-
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules
-
Baum R.P., Prasad V., Muller D., Schuchardt C., Orlova A., Wennborg A., et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 2010, 51:892-897.
-
(2010)
J Nucl Med
, vol.51
, pp. 892-897
-
-
Baum, R.P.1
Prasad, V.2
Muller, D.3
Schuchardt, C.4
Orlova, A.5
Wennborg, A.6
-
226
-
-
33644818017
-
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors
-
Velikyan I., Sundberg A.L., Lindhe O., Hoglund A.U., Eriksson O., Werner E., et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005, 46:1881-1888.
-
(2005)
J Nucl Med
, vol.46
, pp. 1881-1888
-
-
Velikyan, I.1
Sundberg, A.L.2
Lindhe, O.3
Hoglund, A.U.4
Eriksson, O.5
Werner, E.6
-
227
-
-
80054709746
-
Improved tumor-to-organ ratios of a novel (67)Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules
-
Sandstrom K., Haylock A.K., Velikyan I., Spiegelberg D., Kareem H., Tolmachev V., et al. Improved tumor-to-organ ratios of a novel (67)Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules. Cancer Biother Radiopharm 2011, 26:593-601.
-
(2011)
Cancer Biother Radiopharm
, vol.26
, pp. 593-601
-
-
Sandstrom, K.1
Haylock, A.K.2
Velikyan, I.3
Spiegelberg, D.4
Kareem, H.5
Tolmachev, V.6
-
228
-
-
80255124828
-
68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET
-
Kramer-Marek G., Shenoy N., Seidel J., Griffiths G.L., Choyke P., Capala J. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 2011, 38:1967-1976.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 1967-1976
-
-
Kramer-Marek, G.1
Shenoy, N.2
Seidel, J.3
Griffiths, G.L.4
Choyke, P.5
Capala, J.6
-
229
-
-
84902408392
-
-
Synthesis, Characterization and Application of 68Ga-Labelled Macromolecules [Doctorate thesis]. Uppsala: Uppsala University; 2005.
-
Velikyan I. Synthesis, Characterization and Application of 68Ga-Labelled Macromolecules; http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5876 [Doctorate thesis]. Uppsala: Uppsala University; 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5876.
-
-
-
Velikyan, I.1
-
230
-
-
33745574028
-
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET
-
Smith-Jones P.M., Solit D., Afroze F., Rosen N., Larson S.M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006, 47:793-796.
-
(2006)
J Nucl Med
, vol.47
, pp. 793-796
-
-
Smith-Jones, P.M.1
Solit, D.2
Afroze, F.3
Rosen, N.4
Larson, S.M.5
-
231
-
-
2542643923
-
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
-
Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004, 22:701-706.
-
(2004)
Nat Biotechnol
, vol.22
, pp. 701-706
-
-
Smith-Jones, P.M.1
Solit, D.B.2
Akhurst, T.3
Afroze, F.4
Rosen, N.5
Larson, S.M.6
-
232
-
-
69449083591
-
A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression
-
Ren G., Zhang R., Liu Z., Webster J.M., Miao Z., Gambhir S.S., et al. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med 2009, 50:1492-1499.
-
(2009)
J Nucl Med
, vol.50
, pp. 1492-1499
-
-
Ren, G.1
Zhang, R.2
Liu, Z.3
Webster, J.M.4
Miao, Z.5
Gambhir, S.S.6
-
233
-
-
77956143095
-
Rational approach to the synthesis, evaluation, and 68Ga labeling of a novel 4-Anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase
-
Theeraladanon C., Takahashi N., Shiina M., Hamada K., Takada Y., Endo H., et al. Rational approach to the synthesis, evaluation, and 68Ga labeling of a novel 4-Anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase. Cancer Biother Radiopharm 2010, 25:479-485.
-
(2010)
Cancer Biother Radiopharm
, vol.25
, pp. 479-485
-
-
Theeraladanon, C.1
Takahashi, N.2
Shiina, M.3
Hamada, K.4
Takada, Y.5
Endo, H.6
-
234
-
-
15944376260
-
Radioimmunotherapy of prostate cancer
-
Smith-Jones P.M. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 2004, 48:297-304.
-
(2004)
Q J Nucl Med Mol Imaging
, vol.48
, pp. 297-304
-
-
Smith-Jones, P.M.1
-
235
-
-
35048823742
-
Clinical trials of cancer therapies targeting prostate-specific membrane antigen
-
Olson W.C., Heston W.D.W., Rajasekaran A.K. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007, 2:182-190.
-
(2007)
Rev Recent Clin Trials
, vol.2
, pp. 182-190
-
-
Olson, W.C.1
Heston, W.D.W.2
Rajasekaran, A.K.3
-
236
-
-
46749104779
-
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: Lesion detectability and dosimetric projections for 90Y radioimmunotherapy
-
Pandit-Taskar N., O'Donoghue J.A., Morris M.J., Wills E.A., Schwartz L.H., Gonen M., et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: Lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008, 49:1066-1074.
-
(2008)
J Nucl Med
, vol.49
, pp. 1066-1074
-
-
Pandit-Taskar, N.1
O'Donoghue, J.A.2
Morris, M.J.3
Wills, E.A.4
Schwartz, L.H.5
Gonen, M.6
-
237
-
-
20644436713
-
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: Radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen
-
Vallabhajosula S., Goldsmith S.J., Hamacher K.A., Kostakoglu L., Konishi S., Milowski M.I., et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: Radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005, 46:850-858.
-
(2005)
J Nucl Med
, vol.46
, pp. 850-858
-
-
Vallabhajosula, S.1
Goldsmith, S.J.2
Hamacher, K.A.3
Kostakoglu, L.4
Konishi, S.5
Milowski, M.I.6
-
238
-
-
63849194953
-
PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen
-
Elsässer-Beile U., Reischl G., Wiehr S., Bühler P., Wolf P., Alt K., et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009, 50:606-611.
-
(2009)
J Nucl Med
, vol.50
, pp. 606-611
-
-
Elsässer-Beile, U.1
Reischl, G.2
Wiehr, S.3
Bühler, P.4
Wolf, P.5
Alt, K.6
-
239
-
-
33748450568
-
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer
-
Elsässer-Beile U., Wolf P., Gierschner D., Bühler P., Schultze-Seemann W.G., Wetterauer U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006, 66:1359-1370.
-
(2006)
Prostate
, vol.66
, pp. 1359-1370
-
-
Elsässer-Beile, U.1
Wolf, P.2
Gierschner, D.3
Bühler, P.4
Schultze-Seemann, W.G.5
Wetterauer, U.6
-
240
-
-
54949106587
-
Radionuclide-based cancer imaging targeting the carcinoembryonic antigen
-
Hong H., Sun J., Cai W. Radionuclide-based cancer imaging targeting the carcinoembryonic antigen. Biomark Insights 2008, 3:435-451.
-
(2008)
Biomark Insights
, vol.3
, pp. 435-451
-
-
Hong, H.1
Sun, J.2
Cai, W.3
-
241
-
-
72849131940
-
The problem is background, not signal
-
Frangioni J.V. The problem is background, not signal. Mol Imaging 2009, 8:303-304.
-
(2009)
Mol Imaging
, vol.8
, pp. 303-304
-
-
Frangioni, J.V.1
-
242
-
-
77954691424
-
Ga-68-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer
-
Banerjee S.R., Pullambhatla M., Byun Y., Nimmagadda S., Green G., Fox J.J., et al. Ga-68-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010, 53:5333-5341.
-
(2010)
J Med Chem
, vol.53
, pp. 5333-5341
-
-
Banerjee, S.R.1
Pullambhatla, M.2
Byun, Y.3
Nimmagadda, S.4
Green, G.5
Fox, J.J.6
-
243
-
-
84859991899
-
68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging
-
Eder M., Schafer M., Bauder-Wust U., Hull W.E., Wangler C., Mier W., et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012, 23:688-697.
-
(2012)
Bioconjug Chem
, vol.23
, pp. 688-697
-
-
Eder, M.1
Schafer, M.2
Bauder-Wust, U.3
Hull, W.E.4
Wangler, C.5
Mier, W.6
-
244
-
-
84862670770
-
PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
-
Afshar-Oromieh A., Malcher A., Eder M., Eisenhut M., Linhart H.G., Hadaschik B.A., et al. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2012, 39:1085-1086.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 1085-1086
-
-
Afshar-Oromieh, A.1
Malcher, A.2
Eder, M.3
Eisenhut, M.4
Linhart, H.G.5
Hadaschik, B.A.6
-
245
-
-
0027428816
-
Bispecific monoclonal antibody-mediated targeting of an indium-111- labeled DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response
-
Le Doussal J.M., Chetanneau A., Gruaz-Guyon A., Martin M., Gautherot E., Lehur P.A., et al. Bispecific monoclonal antibody-mediated targeting of an indium-111- labeled DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 1993, 34:1662-1671.
-
(1993)
J Nucl Med
, vol.34
, pp. 1662-1671
-
-
Le Doussal, J.M.1
Chetanneau, A.2
Gruaz-Guyon, A.3
Martin, M.4
Gautherot, E.5
Lehur, P.A.6
-
246
-
-
0025148991
-
Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication
-
Kalofonos H.P., Rusckowski M., Siebecker D.A., Sivolapenko G.B., Snook D., Lavender J.P., et al. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med 1990, 31:1791-1796.
-
(1990)
J Nucl Med
, vol.31
, pp. 1791-1796
-
-
Kalofonos, H.P.1
Rusckowski, M.2
Siebecker, D.A.3
Sivolapenko, G.B.4
Snook, D.5
Lavender, J.P.6
-
247
-
-
0031869630
-
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA X anti-DTPA-indium bispecific antibody
-
Barbet J., Peltier P., Bardet S., Vuillez J.P., Bachelot I., Denet S., et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA X anti-DTPA-indium bispecific antibody. J Nucl Med 1998, 39:1172-1178.
-
(1998)
J Nucl Med
, vol.39
, pp. 1172-1178
-
-
Barbet, J.1
Peltier, P.2
Bardet, S.3
Vuillez, J.P.4
Bachelot, I.5
Denet, S.6
-
248
-
-
84864776718
-
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement
-
Salaun P.Y., Campion L., Bournaud C., Faivre-Chauvet A., Vuillez J.P., Taieb D., et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med 2012, 53:1185-1192.
-
(2012)
J Nucl Med
, vol.53
, pp. 1185-1192
-
-
Salaun, P.Y.1
Campion, L.2
Bournaud, C.3
Faivre-Chauvet, A.4
Vuillez, J.P.5
Taieb, D.6
-
249
-
-
10344241996
-
Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer
-
Bardiès M., Bardet S., Faivre-Chauvet A., Peltier P., Douillard J.Y., Mahé M., et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med 1996, 37:1853-1859.
-
(1996)
J Nucl Med
, vol.37
, pp. 1853-1859
-
-
Bardiès, M.1
Bardet, S.2
Faivre-Chauvet, A.3
Peltier, P.4
Douillard, J.Y.5
Mahé, M.6
-
250
-
-
84864559416
-
Pretargeted molecular imaging and radioimmunotherapy
-
Goldenberg D.M., Chang C.H., Rossi E.A., McBride J.W., Sharkey R.M. Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2012, 2:523-540.
-
(2012)
Theranostics
, vol.2
, pp. 523-540
-
-
Goldenberg, D.M.1
Chang, C.H.2
Rossi, E.A.3
McBride, J.W.4
Sharkey, R.M.5
-
251
-
-
0032916670
-
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
-
Paganelli G., Grana C., Chinol M., Cremonesi M., De Cicco C., De Braud F., et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999, 26:348-357.
-
(1999)
Eur J Nucl Med
, vol.26
, pp. 348-357
-
-
Paganelli, G.1
Grana, C.2
Chinol, M.3
Cremonesi, M.4
De Cicco, C.5
De Braud, F.6
-
252
-
-
77949268360
-
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with 90Y-labeled biotin
-
Paganelli G., De Cicco C., Ferrari M.E., Carbone G., Pagani G., Leonardi M.C., et al. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with 90Y-labeled biotin. Eur J Nucl Med Mol Imaging 2010, 37:203-211.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 203-211
-
-
Paganelli, G.1
De Cicco, C.2
Ferrari, M.E.3
Carbone, G.4
Pagani, G.5
Leonardi, M.C.6
-
253
-
-
0038621645
-
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results
-
Siegel B.A., Dehdashti F., Mutch D.G., Podoloff D.A., Wendt R., Sutton G.P., et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003, 44:700-707.
-
(2003)
J Nucl Med
, vol.44
, pp. 700-707
-
-
Siegel, B.A.1
Dehdashti, F.2
Mutch, D.G.3
Podoloff, D.A.4
Wendt, R.5
Sutton, G.P.6
-
254
-
-
44849127008
-
Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors
-
Fisher R.E., Siegel B.A., Edell S.L., Oyesiku N.M., Morgenstern D.E., Messmann R.A., et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 2008, 49:899-906.
-
(2008)
J Nucl Med
, vol.49
, pp. 899-906
-
-
Fisher, R.E.1
Siegel, B.A.2
Edell, S.L.3
Oyesiku, N.M.4
Morgenstern, D.E.5
Messmann, R.A.6
-
255
-
-
0026638808
-
Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by Positron Emission Tomography
-
Liu A., Carlson K.E., Katzenellenbogen J.A. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by Positron Emission Tomography. J Med Chem 1992, 35:2113-2129.
-
(1992)
J Med Chem
, vol.35
, pp. 2113-2129
-
-
Liu, A.1
Carlson, K.E.2
Katzenellenbogen, J.A.3
-
256
-
-
2342599027
-
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer
-
Larson S.M., Morris M., Gunther I., Beattie B., Humm J.L., Akhurst T.A., et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004, 45:366-373.
-
(2004)
J Nucl Med
, vol.45
, pp. 366-373
-
-
Larson, S.M.1
Morris, M.2
Gunther, I.3
Beattie, B.4
Humm, J.L.5
Akhurst, T.A.6
-
257
-
-
75749116783
-
Pharmacokinetic assessment of the uptake of 16{beta}-18F-Fluoro-5{alpha}-dihydrotestosterone (FDHT) in prostate tumors as measured by PET
-
Beattie B.J., Smith-Jones P.M., Jhanwar Y.S., Schoder H., Schmidtlein C.R., Morris M.J., et al. Pharmacokinetic assessment of the uptake of 16{beta}-18F-Fluoro-5{alpha}-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med 2010, 51:183-192.
-
(2010)
J Nucl Med
, vol.51
, pp. 183-192
-
-
Beattie, B.J.1
Smith-Jones, P.M.2
Jhanwar, Y.S.3
Schoder, H.4
Schmidtlein, C.R.5
Morris, M.J.6
-
258
-
-
17644401698
-
Positron tomographic assessment of androgen receptors in prostatic carcinoma
-
Dehdashti F., Picus J., Michalski J.M., Dence C.S., Siegel B.A., Katzenellenbogen J.A., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005, 32:344-350.
-
(2005)
Eur J Nucl Med Mol Imaging
, vol.32
, pp. 344-350
-
-
Dehdashti, F.1
Picus, J.2
Michalski, J.M.3
Dence, C.S.4
Siegel, B.A.5
Katzenellenbogen, J.A.6
-
259
-
-
16544375295
-
PET-based radiation dosimetry in man of18F- fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer
-
Zanzonico P.B., Finn R., Pentlow K.S., Erdi Y., Beattie B., Akhurst T., et al. PET-based radiation dosimetry in man of18F- fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004, 45:1966-1971.
-
(2004)
J Nucl Med
, vol.45
, pp. 1966-1971
-
-
Zanzonico, P.B.1
Finn, R.2
Pentlow, K.S.3
Erdi, Y.4
Beattie, B.5
Akhurst, T.6
-
260
-
-
84860316763
-
68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers
-
Persson M., Madsen J., Ostergaard S., Ploug M., Kjaer A. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 2012, 39:560-569.
-
(2012)
Nucl Med Biol
, vol.39
, pp. 560-569
-
-
Persson, M.1
Madsen, J.2
Ostergaard, S.3
Ploug, M.4
Kjaer, A.5
-
261
-
-
51049094210
-
Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET
-
Li Z.B., Niu G., Wang H., He L., Yang L., Ploug M., et al. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res 2008, 14:4758-4766.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4758-4766
-
-
Li, Z.B.1
Niu, G.2
Wang, H.3
He, L.4
Yang, L.5
Ploug, M.6
-
262
-
-
0033975202
-
PET imaging of adrenal cortical tumors with the 11 β-hydroxylase tracer 11C-metomidate
-
Bergström M., Juhlin C., Bonasera T.A., Sundin A., Rastad J., Åkerström G., et al. PET imaging of adrenal cortical tumors with the 11 β-hydroxylase tracer 11C-metomidate. J Nucl Med 2000, 41:275-282.
-
(2000)
J Nucl Med
, vol.41
, pp. 275-282
-
-
Bergström, M.1
Juhlin, C.2
Bonasera, T.A.3
Sundin, A.4
Rastad, J.5
Åkerström, G.6
-
263
-
-
33646027924
-
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings
-
Hennings J., Lindhe O., Bergstrom M., Langstrom B., Sundin A., Hellman P. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006, 91:1410-1414.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 1410-1414
-
-
Hennings, J.1
Lindhe, O.2
Bergstrom, M.3
Langstrom, B.4
Sundin, A.5
Hellman, P.6
-
264
-
-
84857132048
-
Cationic lipophilic radiotracers for functional imaging of multidrug resistance
-
Gomes C.M.F. Cationic lipophilic radiotracers for functional imaging of multidrug resistance. Curr Radiopharm 2012, 5:113-123.
-
(2012)
Curr Radiopharm
, vol.5
, pp. 113-123
-
-
Gomes, C.M.F.1
-
265
-
-
33750587112
-
Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil
-
Takano A., Kusuhara H., Suhara T., Ieiri I., Morimoto T., Lee Y.J., et al. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med 2006, 47:1427-1433.
-
(2006)
J Nucl Med
, vol.47
, pp. 1427-1433
-
-
Takano, A.1
Kusuhara, H.2
Suhara, T.3
Ieiri, I.4
Morimoto, T.5
Lee, Y.J.6
-
266
-
-
0033622160
-
Evaluation of 11C-colchicine for PET imaging of multiple drug resistance
-
Levchenko A., Mehta B.M., Lee J.B., Humm J.L., Augensen F., Squire O., et al. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med 2000, 41:493-501.
-
(2000)
J Nucl Med
, vol.41
, pp. 493-501
-
-
Levchenko, A.1
Mehta, B.M.2
Lee, J.B.3
Humm, J.L.4
Augensen, F.5
Squire, O.6
-
267
-
-
79952108774
-
Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with Ga-68-labelled PET tracer
-
Thews O., Dillenburg W., Fellner M., Buchholz H.G., Bausbacher N., Schreckenberger M., et al. Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with Ga-68-labelled PET tracer. Eur J Nucl Med Mol Imaging 2010, 37:1935-1942.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 1935-1942
-
-
Thews, O.1
Dillenburg, W.2
Fellner, M.3
Buchholz, H.G.4
Bausbacher, N.5
Schreckenberger, M.6
-
268
-
-
84855659651
-
Assessing p-glycoprotein (Pgp) activity in vivo utilizing 68Ga-Schiff base complexes
-
Fellner M., Dillenburg W., Buchholz H.G., Bausbacher N., Schreckenberger M., Renz F., et al. Assessing p-glycoprotein (Pgp) activity in vivo utilizing 68Ga-Schiff base complexes. Mol Imaging Biol 2011, 13:985-994.
-
(2011)
Mol Imaging Biol
, vol.13
, pp. 985-994
-
-
Fellner, M.1
Dillenburg, W.2
Buchholz, H.G.3
Bausbacher, N.4
Schreckenberger, M.5
Renz, F.6
-
269
-
-
36048954536
-
The national oncologic pet registry (NOPR): design and analysis plan
-
Hillner B.E., Liu D., Coleman R.E., Shields A.F., Gareen I.F., Hanna L., et al. The national oncologic pet registry (NOPR): design and analysis plan. J Nucl Med 2007, 48:1901-1908.
-
(2007)
J Nucl Med
, vol.48
, pp. 1901-1908
-
-
Hillner, B.E.1
Liu, D.2
Coleman, R.E.3
Shields, A.F.4
Gareen, I.F.5
Hanna, L.6
-
270
-
-
79957760097
-
The next generation of positron emission tomography radiopharmaceuticals in oncology
-
Rice S.L., Roney C.A., Daumar P., Lewis J.S. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med 2011, 41:265-282.
-
(2011)
Semin Nucl Med
, vol.41
, pp. 265-282
-
-
Rice, S.L.1
Roney, C.A.2
Daumar, P.3
Lewis, J.S.4
-
271
-
-
33646833930
-
Positron emission tomography with c11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy
-
Sandblom G., Sörensen J., Lundin N., Häggman M., Malmström P.U. Positron emission tomography with c11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006, 67:996-1000.
-
(2006)
Urology
, vol.67
, pp. 996-1000
-
-
Sandblom, G.1
Sörensen, J.2
Lundin, N.3
Häggman, M.4
Malmström, P.U.5
-
272
-
-
34548570102
-
Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)thymine and PET
-
Tehrani O.S., Muzik O., Heilbrun L.K., Douglas K.A., Lawhorn-Crews J.M., Sun H., et al. Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)thymine and PET. J Nucl Med 2007, 48:1436-1441.
-
(2007)
J Nucl Med
, vol.48
, pp. 1436-1441
-
-
Tehrani, O.S.1
Muzik, O.2
Heilbrun, L.K.3
Douglas, K.A.4
Lawhorn-Crews, J.M.5
Sun, H.6
-
273
-
-
74849100940
-
I-131-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors
-
Grunwald F., Ezziddin S. I-131-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2010, 40:153-163.
-
(2010)
Semin Nucl Med
, vol.40
, pp. 153-163
-
-
Grunwald, F.1
Ezziddin, S.2
-
274
-
-
14944373233
-
Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas
-
Ribom D., Schoenmaekers M., Engler H., Smits A. Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas. J Neurooncol 2005, 71:325-332.
-
(2005)
J Neurooncol
, vol.71
, pp. 325-332
-
-
Ribom, D.1
Schoenmaekers, M.2
Engler, H.3
Smits, A.4
-
275
-
-
42449130011
-
High success rate of parathyroid reoperation may be achieved with improved localization diagnosis
-
discussion 82-3
-
Hessman O., Stalberg P., Sundin A., Garske U., Rudberg C., Eriksson L.G., et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg 2008, 32:774-781. discussion 82-3.
-
(2008)
World J Surg
, vol.32
, pp. 774-781
-
-
Hessman, O.1
Stalberg, P.2
Sundin, A.3
Garske, U.4
Rudberg, C.5
Eriksson, L.G.6
-
276
-
-
21244471142
-
Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography
-
Orlefors H., Sundin A., Garske U., Juhlin C., Oberg K., Skogseid B., et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005, 90:3392-3400.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 3392-3400
-
-
Orlefors, H.1
Sundin, A.2
Garske, U.3
Juhlin, C.4
Oberg, K.5
Skogseid, B.6
-
277
-
-
84873995044
-
Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer
-
Sörensen J., Owenius R., Lax M., Johansson S. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging 2013, 40:394-402.
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, pp. 394-402
-
-
Sörensen, J.1
Owenius, R.2
Lax, M.3
Johansson, S.4
-
278
-
-
84856802355
-
Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis
-
Dunet V., Rossier C., Buck A., Stupp R., Prior J.O. Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 2012, 53:207-214.
-
(2012)
J Nucl Med
, vol.53
, pp. 207-214
-
-
Dunet, V.1
Rossier, C.2
Buck, A.3
Stupp, R.4
Prior, J.O.5
-
279
-
-
79957962933
-
Three-dimensional radiobiological dosimetry (3D-RD) with I-124 PET for I-131 therapy of thyroid cancer
-
Sgouros G., Hobbs R.F., Atkins F.B., Van Nostrand D., Ladenson P.W., Wahl R.L. Three-dimensional radiobiological dosimetry (3D-RD) with I-124 PET for I-131 therapy of thyroid cancer. Eur J Nucl Med Mol Imaging 2011, 38:41-47.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 41-47
-
-
Sgouros, G.1
Hobbs, R.F.2
Atkins, F.B.3
Van Nostrand, D.4
Ladenson, P.W.5
Wahl, R.L.6
-
280
-
-
22444444683
-
Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review
-
Bauman G., Charette M., Reid R., Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol 2005, 75:258-270.
-
(2005)
Radiother Oncol
, vol.75
, pp. 258-270
-
-
Bauman, G.1
Charette, M.2
Reid, R.3
Sathya, J.4
-
281
-
-
16844381500
-
Imaging apoptosis in vivo using 124I-annexin V and PET
-
Keen H.G., Dekker B.A., Disley L., Hastings D., Lyons S., Reader A.J., et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol 2005, 32:395-402.
-
(2005)
Nucl Med Biol
, vol.32
, pp. 395-402
-
-
Keen, H.G.1
Dekker, B.A.2
Disley, L.3
Hastings, D.4
Lyons, S.5
Reader, A.J.6
-
282
-
-
34547772626
-
Effect of postconditioning on myocardial 99mTc-annexin-V uptake: comparison with ischemic preconditioning and caspase inhibitor treatment
-
Taki J., Higuchi T., Kawashima A., Fukuoka M., Kayano D., Tait J.F., et al. Effect of postconditioning on myocardial 99mTc-annexin-V uptake: comparison with ischemic preconditioning and caspase inhibitor treatment. J Nucl Med 2007, 48:1301-1307.
-
(2007)
J Nucl Med
, vol.48
, pp. 1301-1307
-
-
Taki, J.1
Higuchi, T.2
Kawashima, A.3
Fukuoka, M.4
Kayano, D.5
Tait, J.F.6
-
283
-
-
1642358348
-
Production of [F-18]fluoroannexin for imaging apoptosis with PET
-
Grierson J.R., Yagle K.J., Eary J.F., Tait J.F., Gibson D.F., Lewellen B., et al. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjug Chem 2004, 15:373-379.
-
(2004)
Bioconjug Chem
, vol.15
, pp. 373-379
-
-
Grierson, J.R.1
Yagle, K.J.2
Eary, J.F.3
Tait, J.F.4
Gibson, D.F.5
Lewellen, B.6
-
284
-
-
79954419481
-
Site-specific Ga-68-labeled Annexin A5 as a PET imaging agent for apoptosis
-
Bauwens M., De Saint-Hubert M., Devos E., Deckers N., Reutelingsperger C., Mortelmans L., et al. Site-specific Ga-68-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol 2011, 38:381-392.
-
(2011)
Nucl Med Biol
, vol.38
, pp. 381-392
-
-
Bauwens, M.1
De Saint-Hubert, M.2
Devos, E.3
Deckers, N.4
Reutelingsperger, C.5
Mortelmans, L.6
-
285
-
-
79953222548
-
Synthesis of Ga-68-labeled DOTA-nitroimidazole derivatives and their feasibilities as hypoxia imaging PET tracers
-
Hoigebazar L., Jeong J.M., Hong M.K., Young J.K., Lee J.Y., Shetty D., et al. Synthesis of Ga-68-labeled DOTA-nitroimidazole derivatives and their feasibilities as hypoxia imaging PET tracers. Bioorg Med Chem 2011, 19:2176-2181.
-
(2011)
Bioorg Med Chem
, vol.19
, pp. 2176-2181
-
-
Hoigebazar, L.1
Jeong, J.M.2
Hong, M.K.3
Young, J.K.4
Lee, J.Y.5
Shetty, D.6
-
286
-
-
77956302003
-
Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice
-
Hoigebazar L., Jeong J.M., Choi S.Y., Choi J.Y., Shetty D., Lee Y.S., et al. Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice. J Med Chem 2010, 53:6378-6385.
-
(2010)
J Med Chem
, vol.53
, pp. 6378-6385
-
-
Hoigebazar, L.1
Jeong, J.M.2
Choi, S.Y.3
Choi, J.Y.4
Shetty, D.5
Lee, Y.S.6
-
287
-
-
66449109838
-
Design of Ga-DOTA-based bifunctional radiopharmaceuticals: two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability
-
Mukai T., Suwada J., Sano K., Okada M., Yamamoto F., Maeda M. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability. Bioorg Med Chem 2009, 17:4285-4289.
-
(2009)
Bioorg Med Chem
, vol.17
, pp. 4285-4289
-
-
Mukai, T.1
Suwada, J.2
Sano, K.3
Okada, M.4
Yamamoto, F.5
Maeda, M.6
-
288
-
-
84872955946
-
Synthesis, in vitro and in vivo characterization of two novel (68)Ga-labelled 5-nitroimidazole derivatives as potential agents for imaging hypoxia
-
Fernandez S., Dematteis S., Giglio J., Cerecetto H., Rey A. Synthesis, in vitro and in vivo characterization of two novel (68)Ga-labelled 5-nitroimidazole derivatives as potential agents for imaging hypoxia. Nucl Med Biol. 2013, 40(2):273-279.
-
(2013)
Nucl Med Biol.
, vol.40
, Issue.2
, pp. 273-279
-
-
Fernandez, S.1
Dematteis, S.2
Giglio, J.3
Cerecetto, H.4
Rey, A.5
-
289
-
-
33751543273
-
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy
-
Tatum J.L., Kelloff G.J., Gillies R.J., Arbeit J.M., Brown J.M., Chao K.S., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
-
(2006)
Int J Radiat Biol
, vol.82
, pp. 699-757
-
-
Tatum, J.L.1
Kelloff, G.J.2
Gillies, R.J.3
Arbeit, J.M.4
Brown, J.M.5
Chao, K.S.6
-
290
-
-
0030249455
-
Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients
-
Rasey J.S., Koh W.J., Evans M.L., Peterson L.M., Lewellen T.K., Graham M.M., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36:417-428.
-
(1996)
Int J Radiat Oncol Biol Phys
, vol.36
, pp. 417-428
-
-
Rasey, J.S.1
Koh, W.J.2
Evans, M.L.3
Peterson, L.M.4
Lewellen, T.K.5
Graham, M.M.6
-
291
-
-
0029933781
-
Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside
-
Urtasun R.C., Parliament M.B., McEwan A.J., Mercer J.R., Mannan R.H., Wiebe L.I., et al. Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. Br J Cancer Suppl 1996, 27:S209-S212.
-
(1996)
Br J Cancer Suppl
, vol.27
-
-
Urtasun, R.C.1
Parliament, M.B.2
McEwan, A.J.3
Mercer, J.R.4
Mannan, R.H.5
Wiebe, L.I.6
-
292
-
-
0035869722
-
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy
-
Chao K.S., Bosch W.R., Mutic S., Lewis J.S., Dehdashti F., Mintun M.A., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001, 49:1171-1182.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.49
, pp. 1171-1182
-
-
Chao, K.S.1
Bosch, W.R.2
Mutic, S.3
Lewis, J.S.4
Dehdashti, F.5
Mintun, M.A.6
-
293
-
-
0242417596
-
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report
-
Dehdashti F., Grigsby P.W., Mintun M.A., Lewis J.S., Siegel B.A., Welch M.J. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55:1233-1238.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.55
, pp. 1233-1238
-
-
Dehdashti, F.1
Grigsby, P.W.2
Mintun, M.A.3
Lewis, J.S.4
Siegel, B.A.5
Welch, M.J.6
-
294
-
-
0038376175
-
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM
-
Dehdashti F., Mintun M.A., Lewis J.S., Bradley J., Govindan R., Laforest R., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
-
(2003)
Eur J Nucl Med Mol Imaging
, vol.30
, pp. 844-850
-
-
Dehdashti, F.1
Mintun, M.A.2
Lewis, J.S.3
Bradley, J.4
Govindan, R.5
Laforest, R.6
-
296
-
-
33745548133
-
PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression
-
Beer A.J., Haubner R., Wolf I., Goebel M., Luderschmidt S., Niemeyer M., et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006, 47:763-769.
-
(2006)
J Nucl Med
, vol.47
, pp. 763-769
-
-
Beer, A.J.1
Haubner, R.2
Wolf, I.3
Goebel, M.4
Luderschmidt, S.5
Niemeyer, M.6
-
297
-
-
36749053493
-
[18F]Galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck
-
Beer A.J., Grosu A.L., Carlsen J., Kolk A., Sarbia M., Stangier I., et al. [18F]Galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:6610-6616.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6610-6616
-
-
Beer, A.J.1
Grosu, A.L.2
Carlsen, J.3
Kolk, A.4
Sarbia, M.5
Stangier, I.6
-
299
-
-
85031247149
-
-
68Ga-labeled peptide-based radiopharmaceuticals. U.S.A. Patent No: WO/2008/026040
-
Velikyan I, Långström B, Bergström M, Lindhe Ö. 68Ga-labeled peptide-based radiopharmaceuticals. U.S.A. Patent No: WO/2008/026040; 200.
-
Långström B, Bergström M, Lindhe Ö.
, pp. 200
-
-
Velikyan, I.1
-
300
-
-
44149120982
-
Preparation of a promising angiogenesis PET imaging agent: Ga-68-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice
-
Jeong J.M., Hong M.K., Chang Y.S., Lee Y.S., Kim Y.J., Cheon G.J., et al. Preparation of a promising angiogenesis PET imaging agent: Ga-68-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008, 49:830-836.
-
(2008)
J Nucl Med
, vol.49
, pp. 830-836
-
-
Jeong, J.M.1
Hong, M.K.2
Chang, Y.S.3
Lee, Y.S.4
Kim, Y.J.5
Cheon, G.J.6
-
301
-
-
71849109948
-
(68)Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice
-
Haukkala J., Laitinen I., Luoto P., Iveson P., Wilson I., Karlsen H., et al. (68)Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging 2009, 36(12):2058-2067.
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, Issue.12
, pp. 2058-2067
-
-
Haukkala, J.1
Laitinen, I.2
Luoto, P.3
Iveson, P.4
Wilson, I.5
Karlsen, H.6
-
302
-
-
80051700245
-
Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis
-
Dumont R.A., Deininger F., Haubner R., Maecke H.R., Weber W.A., Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis. J Nucl Med 2011, 52:1276-1284.
-
(2011)
J Nucl Med
, vol.52
, pp. 1276-1284
-
-
Dumont, R.A.1
Deininger, F.2
Haubner, R.3
Maecke, H.R.4
Weber, W.A.5
Fani, M.6
-
303
-
-
79958025504
-
[68Ga]NODAGA-RGD for imaging alphavbeta3 integrin expression
-
Knetsch P.A., Petrik M., Griessinger C.M., Rangger C., Fani M., Kesenheimer C., et al. [68Ga]NODAGA-RGD for imaging alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2011, 38:1303-1312.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 1303-1312
-
-
Knetsch, P.A.1
Petrik, M.2
Griessinger, C.M.3
Rangger, C.4
Fani, M.5
Kesenheimer, C.6
-
304
-
-
84863990736
-
68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process
-
Pohle K., Notni J., Bussemer J., Kessler H., Schwaiger M., Beer A.J. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol 2012, 39:777-784.
-
(2012)
Nucl Med Biol
, vol.39
, pp. 777-784
-
-
Pohle, K.1
Notni, J.2
Bussemer, J.3
Kessler, H.4
Schwaiger, M.5
Beer, A.J.6
-
305
-
-
84869752698
-
(68)Ga small peptide imaging: comparison of NOTA and PCTA
-
Ferreira C.L., Yapp D.T., Mandel D., Gill R.K., Boros E., Wong M.Q., et al. (68)Ga small peptide imaging: comparison of NOTA and PCTA. Bioconjug Chem 2012, 23:2239-2246.
-
(2012)
Bioconjug Chem
, vol.23
, pp. 2239-2246
-
-
Ferreira, C.L.1
Yapp, D.T.2
Mandel, D.3
Gill, R.K.4
Boros, E.5
Wong, M.Q.6
-
306
-
-
84859976754
-
(68)Ga-Labeling of RGD peptides and biodistribution
-
Blom E., Velikyan I., Estrada S., Hall H., Muhammad T., Ding C., et al. (68)Ga-Labeling of RGD peptides and biodistribution. Int J Clin Exp Med 2012, 5:165-172.
-
(2012)
Int J Clin Exp Med
, vol.5
, pp. 165-172
-
-
Blom, E.1
Velikyan, I.2
Estrada, S.3
Hall, H.4
Muhammad, T.5
Ding, C.6
-
307
-
-
43749105336
-
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression
-
Li Z.B., Chen K., Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging 2008, 35:1100-1108.
-
(2008)
Eur J Nucl Med Mol Imaging
, vol.35
, pp. 1100-1108
-
-
Li, Z.B.1
Chen, K.2
Chen, X.3
-
308
-
-
79551515411
-
PET imaging of alphavbeta integrin expression in tumours with Ga-labelled mono-, di- and tetrameric RGD peptides
-
Dijkgraaf I., Yim C.B., Franssen G.M., Schuit R.C., Luurtsema G., Liu S., et al. PET imaging of alphavbeta integrin expression in tumours with Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2011, 38:128-137.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 128-137
-
-
Dijkgraaf, I.1
Yim, C.B.2
Franssen, G.M.3
Schuit, R.C.4
Luurtsema, G.5
Liu, S.6
-
309
-
-
80051762411
-
Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency
-
Singh A.N., Liu W., Hao G.Y., Kumar A., Gupta A., Oz O.K., et al. Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency. Bioconjugate Chem 2011, 22:1650-1662.
-
(2011)
Bioconjugate Chem
, vol.22
, pp. 1650-1662
-
-
Singh, A.N.1
Liu, W.2
Hao, G.Y.3
Kumar, A.4
Gupta, A.5
Oz, O.K.6
-
310
-
-
67349145987
-
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging
-
Liu Z., Niu G., Shi J., Liu S., Wang F., Chen X. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 2009, 36:947-957.
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, pp. 947-957
-
-
Liu, Z.1
Niu, G.2
Shi, J.3
Liu, S.4
Wang, F.5
Chen, X.6
-
311
-
-
84864543385
-
Imaging key biomarkers of tumor angiogenesis
-
Backer M.V., Backer J.M. Imaging key biomarkers of tumor angiogenesis. Theranostics 2012, 2:502-515.
-
(2012)
Theranostics
, vol.2
, pp. 502-515
-
-
Backer, M.V.1
Backer, J.M.2
-
312
-
-
84934442275
-
Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins
-
Backer M.V., Levashova Z., Levenson R., Blankenberg F.G., Backer J.M. Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol 2008, 494:275-294.
-
(2008)
Methods Mol Biol
, vol.494
, pp. 275-294
-
-
Backer, M.V.1
Levashova, Z.2
Levenson, R.3
Blankenberg, F.G.4
Backer, J.M.5
-
313
-
-
77952543436
-
ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature
-
Eder M., Krivoshein A.V., Backer M., Backer J.M., Haberkorn U., Eisenhut M. ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol 2010, 37:405-412.
-
(2010)
Nucl Med Biol
, vol.37
, pp. 405-412
-
-
Eder, M.1
Krivoshein, A.V.2
Backer, M.3
Backer, J.M.4
Haberkorn, U.5
Eisenhut, M.6
-
314
-
-
80054778324
-
Synthesis and characterization of scVEGF-PEG-[68Ga]NOTA and scVEGF-PEG-[68Ga]DOTA PET tracers
-
Blom E., Velikyan I., Monazzam A., Razifar P., Nair M., Razifar P., et al. Synthesis and characterization of scVEGF-PEG-[68Ga]NOTA and scVEGF-PEG-[68Ga]DOTA PET tracers. J Labelled Comp Radiopharm 2011, 54(11):685-692.
-
(2011)
J Labelled Comp Radiopharm
, vol.54
, Issue.11
, pp. 685-692
-
-
Blom, E.1
Velikyan, I.2
Monazzam, A.3
Razifar, P.4
Nair, M.5
Razifar, P.6
-
315
-
-
77956644470
-
Matrix metalloproteinase 9 targeting peptides: syntheses, Ga-68-labeling, and preliminary evaluation in a rat melanoma xenograft model
-
Ujula T., Huttunen M., Luoto P., Perakyla H., Simpura I., Wilson I., et al. Matrix metalloproteinase 9 targeting peptides: syntheses, Ga-68-labeling, and preliminary evaluation in a rat melanoma xenograft model. Bioconjug Chem 2010, 21:1612-1621.
-
(2010)
Bioconjug Chem
, vol.21
, pp. 1612-1621
-
-
Ujula, T.1
Huttunen, M.2
Luoto, P.3
Perakyla, H.4
Simpura, I.5
Wilson, I.6
-
316
-
-
79958290869
-
Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide
-
Azhdarinia A., Wilganowski N., Robinson H., Ghosh P., Kwon S., Lazard Z.W., et al. Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide. Bioorg Med Chem 2011, 19:3769-3776.
-
(2011)
Bioorg Med Chem
, vol.19
, pp. 3769-3776
-
-
Azhdarinia, A.1
Wilganowski, N.2
Robinson, H.3
Ghosh, P.4
Kwon, S.5
Lazard, Z.W.6
-
317
-
-
0037106384
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin
-
Herbst R.S., Mullani N.A., Davis D.W., Hess K.R., McConkey D.J., Charnsangavej C., et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002, 20:3804-3814.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3804-3814
-
-
Herbst, R.S.1
Mullani, N.A.2
Davis, D.W.3
Hess, K.R.4
McConkey, D.J.5
Charnsangavej, C.6
-
318
-
-
34247253782
-
Differentiation of recurrent astrocytoma from radiation necrosis: A pilot study with 13N-NH3 PET
-
Xiangsong Z., Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: A pilot study with 13N-NH3 PET. J Neurooncol 2007, 82:305-311.
-
(2007)
J Neurooncol
, vol.82
, pp. 305-311
-
-
Xiangsong, Z.1
Weian, C.2
-
319
-
-
77956209027
-
The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment
-
Ahmadzadehfar H., Sabet A., Biermann K., Muckle M., Brockmann H., Kuhl C., et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 2010, 51:1206-1212.
-
(2010)
J Nucl Med
, vol.51
, pp. 1206-1212
-
-
Ahmadzadehfar, H.1
Sabet, A.2
Biermann, K.3
Muckle, M.4
Brockmann, H.5
Kuhl, C.6
-
320
-
-
84856770809
-
Dosimetry based on 99mTc-Macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results
-
Garin E., Lenoir L., Rolland Y., Edeline J., Mesbah H., Laffont S., et al. Dosimetry based on 99mTc-Macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 2012, 53:255-263.
-
(2012)
J Nucl Med
, vol.53
, pp. 255-263
-
-
Garin, E.1
Lenoir, L.2
Rolland, Y.3
Edeline, J.4
Mesbah, H.5
Laffont, S.6
-
321
-
-
84875801677
-
Predictive value of intratumoral 99mTc-Macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-Mircrospheres
-
Ulrich G., Dudeck O., Furth C., Ruf J., Grosser O.S., Adolf D., et al. Predictive value of intratumoral 99mTc-Macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-Mircrospheres. J Nucl Med 2013, 54:516-522.
-
(2013)
J Nucl Med
, vol.54
, pp. 516-522
-
-
Ulrich, G.1
Dudeck, O.2
Furth, C.3
Ruf, J.4
Grosser, O.S.5
Adolf, D.6
-
322
-
-
0035108142
-
Intratumoral arteriovenous shunting in malignant gliomas
-
Mariani L., Schroth G., Wielepp J.P., Haldemann A., Seiler R.W. Intratumoral arteriovenous shunting in malignant gliomas. Neurosurgery 2001, 48:353-357.
-
(2001)
Neurosurgery
, vol.48
, pp. 353-357
-
-
Mariani, L.1
Schroth, G.2
Wielepp, J.P.3
Haldemann, A.4
Seiler, R.W.5
-
323
-
-
7044231876
-
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma
-
Geschwind J.F., Salem R., Carr B.I., Soulen M.C., Thurston K.G., Goin K.A., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004, 127:S194-S205.
-
(2004)
Gastroenterology
, vol.127
-
-
Geschwind, J.F.1
Salem, R.2
Carr, B.I.3
Soulen, M.C.4
Thurston, K.G.5
Goin, K.A.6
-
324
-
-
1842558424
-
Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis
-
Salem R., Lewandowski R., Roberts C., Goin J., Thurston K., Abouljoud M., et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004, 15:335-345.
-
(2004)
J Vasc Interv Radiol
, vol.15
, pp. 335-345
-
-
Salem, R.1
Lewandowski, R.2
Roberts, C.3
Goin, J.4
Thurston, K.5
Abouljoud, M.6
-
325
-
-
0000377097
-
Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma
-
Liu L., Jiang Z., Teng G.J., Song J.Z., Zhang D.S., Guo Q.M., et al. Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma. World J Gastroenterol 1999, 5:492-505.
-
(1999)
World J Gastroenterol
, vol.5
, pp. 492-505
-
-
Liu, L.1
Jiang, Z.2
Teng, G.J.3
Song, J.Z.4
Zhang, D.S.5
Guo, Q.M.6
-
326
-
-
22244476442
-
Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results
-
Murthy R., Xiong H., Nunez R., Cohen A.C., Barron B., Szklaruk J., et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005, 16:937-945.
-
(2005)
J Vasc Interv Radiol
, vol.16
, pp. 937-945
-
-
Murthy, R.1
Xiong, H.2
Nunez, R.3
Cohen, A.C.4
Barron, B.5
Szklaruk, J.6
-
327
-
-
84868214422
-
The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: A comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care
-
Tokin C.A., Cope F.O., Metz W.L., Blue M.S., Potter B.M., Abbruzzese B.C., et al. The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: A comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care. Clin Exp Metastasis 2012, 29:681-686.
-
(2012)
Clin Exp Metastasis
, vol.29
, pp. 681-686
-
-
Tokin, C.A.1
Cope, F.O.2
Metz, W.L.3
Blue, M.S.4
Potter, B.M.5
Abbruzzese, B.C.6
-
328
-
-
84864554438
-
Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT
-
Vees H., Steiner C., Dipasquale G., Chouiter A., Zilli T., Velazquez M., et al. Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT. Radiat Oncol 2012, 7(1):134.
-
(2012)
Radiat Oncol
, vol.7
, Issue.1
, pp. 134
-
-
Vees, H.1
Steiner, C.2
Dipasquale, G.3
Chouiter, A.4
Zilli, T.5
Velazquez, M.6
-
329
-
-
67849118622
-
Diagnostic nanocarriers for sentinel lymph node imaging
-
Jain R., Dandekar P., Patravale V. Diagnostic nanocarriers for sentinel lymph node imaging. J Control Release 2009, 138:90-102.
-
(2009)
J Control Release
, vol.138
, pp. 90-102
-
-
Jain, R.1
Dandekar, P.2
Patravale, V.3
-
330
-
-
77958457910
-
Labelling of commercially available human serum albumin kits with 68Ga as surrogates for 99mTc-MAA microspheres
-
Maus S., Buchholz H.-G., Ament S., Brochhausen C., Bausbacher N., Schreckenberger M. Labelling of commercially available human serum albumin kits with 68Ga as surrogates for 99mTc-MAA microspheres. Appl Radiat Isot 2011, 69:171-175.
-
(2011)
Appl Radiat Isot
, vol.69
, pp. 171-175
-
-
Maus, S.1
Buchholz, H.-G.2
Ament, S.3
Brochhausen, C.4
Bausbacher, N.5
Schreckenberger, M.6
-
331
-
-
79954414353
-
Development of Ga-68-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography
-
Choi J.Y., Jeong J.M., Yoo B.C., Kim K., Kim Y., Yang B.Y., et al. Development of Ga-68-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography. Nucl Med Biol 2011, 38:371-379.
-
(2011)
Nucl Med Biol
, vol.38
, pp. 371-379
-
-
Choi, J.Y.1
Jeong, J.M.2
Yoo, B.C.3
Kim, K.4
Kim, Y.5
Yang, B.Y.6
-
332
-
-
84862776518
-
In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene
-
Hong H., Zhang Y., Engle J.W., Nayak T.R., Theuer C.P., Nickles R.J., et al. In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene. Biomaterials 2012, 33:4147-4156.
-
(2012)
Biomaterials
, vol.33
, pp. 4147-4156
-
-
Hong, H.1
Zhang, Y.2
Engle, J.W.3
Nayak, T.R.4
Theuer, C.P.5
Nickles, R.J.6
-
333
-
-
84866174451
-
Nanoparticles modified by encapsulation of ligands with a long alkyl chain to affect multispecific and multimodal imaging
-
Lee Y.K., Jeong J.M., Hoigebazar L., Yang B.Y., Lee Y.S., Lee B.C., et al. Nanoparticles modified by encapsulation of ligands with a long alkyl chain to affect multispecific and multimodal imaging. J Nucl Med 2012, 53:1462-1470.
-
(2012)
J Nucl Med
, vol.53
, pp. 1462-1470
-
-
Lee, Y.K.1
Jeong, J.M.2
Hoigebazar, L.3
Yang, B.Y.4
Lee, Y.S.5
Lee, B.C.6
-
334
-
-
79952588218
-
Preparation of a versatile bifunctional zeolite for targeted imaging applications
-
Ndiege N., Raidoo R., Schultz M.K., Larsen S. Preparation of a versatile bifunctional zeolite for targeted imaging applications. Langmuir 2011, 27(6):2904-2909.
-
(2011)
Langmuir
, vol.27
, Issue.6
, pp. 2904-2909
-
-
Ndiege, N.1
Raidoo, R.2
Schultz, M.K.3
Larsen, S.4
-
335
-
-
75149193491
-
A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer
-
Hwang D.W., Ko H.Y., Lee J.H., Kang H., Ryu S.H., Song I.C., et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010, 51:98-105.
-
(2010)
J Nucl Med
, vol.51
, pp. 98-105
-
-
Hwang, D.W.1
Ko, H.Y.2
Lee, J.H.3
Kang, H.4
Ryu, S.H.5
Song, I.C.6
-
336
-
-
77955657760
-
Triaza-based amphiphilic chelators: synthetic route, in vitro characterization and in vivo studies of their Ga(III) and Al(III) chelates
-
de Sa A., Prata M.I.M., Geraldes C., Andre J.P. Triaza-based amphiphilic chelators: synthetic route, in vitro characterization and in vivo studies of their Ga(III) and Al(III) chelates. J Inorg Biochem 2010, 104:1051-1062.
-
(2010)
J Inorg Biochem
, vol.104
, pp. 1051-1062
-
-
de Sa, A.1
Prata, M.I.M.2
Geraldes, C.3
Andre, J.P.4
-
337
-
-
79954416108
-
Ga(III) chelates of amphiphilic DOTA-based ligands: synthetic route and in vitro and in vivo studies
-
Fontes A., Prata M.I.M., Geraldes C., Andre J.P. Ga(III) chelates of amphiphilic DOTA-based ligands: synthetic route and in vitro and in vivo studies. Nucl Med Biol 2011, 38:363-370.
-
(2011)
Nucl Med Biol
, vol.38
, pp. 363-370
-
-
Fontes, A.1
Prata, M.I.M.2
Geraldes, C.3
Andre, J.P.4
|